

EL897872861US

JC07 Rec'd PCT/PTO 18 DEC 2001

FORM PTO-1500 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 11-2000)		ATTORNEY'S DOCKET NO 150070.401USPC
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO (if known, see 37 CFR 1.5) Unknown 10/018963
		PRIORITY DATE CLAIMED 18 June 1999 (18.06.99)
INTERNATIONAL APPLICATION NO PCT/AU00/00680	INTERNATIONAL FILING DATE 16 June 2000 (16.06.00)	
TITLE OF INVENTION ANTIVIRAL AGENTS		
APPLICANT(S) FOR DO/EO/US WU, Wen Yang; WATSON, Keith; MCCONNELL, Darryl; JIN, Betty and KRIPPNER, Guy		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31) 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4) 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau) b. <input type="checkbox"/> have been communicated by the International Bureau c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired d. <input checked="" type="checkbox"/> have not been made and will not be made 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)) 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5))		
Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included 13. <input type="checkbox"/> A FIRST preliminary amendment 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment 15. <input type="checkbox"/> A substitute specification 16. <input type="checkbox"/> A change of power of attorney and/or address letter 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 35 U.S.C. 1.821 - 1.825 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4) 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4) 20. <input type="checkbox"/> Other items of information		

U.S. APPLICATION NO. (if known, see 37 CFR 1.51) 10/018963 Unknown	INTERNATIONAL APPLICATION NO PCT/AU00/00680	ATTORNEY'S DOCKET NUMBER 150070.401USPC
21. <input checked="" type="checkbox"/> The following fees are submitted Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000 00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860 00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710 00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690 00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00		CALCULATIONS PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$1,000 00
Surcharge of \$130 00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(c)).		\$130 00
Claims	Number Filed	Number Extra
Total Claims	31 - 20 =	11
Independent Claims	10 - 3 =	7
Multiple dependent claim(s) (if applicable)		+ \$270 00
TOTAL OF ABOVE CALCULATIONS =		\$1,888 00
<input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27 The fees indicated above are reduced by 1/2		\$ 00
SUBTOTAL =		\$1,888 00
Processing fee of \$130 00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 00
TOTAL NATIONAL FEE =		\$1,888 00
Fee for recording the enclosed assignment (37 CFR 1.21(h)) The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) \$40.00 per property		\$ 00
TOTAL FEES ENCLOSED =		\$1,888.00
		Amount to be refunded charged
a. <input checked="" type="checkbox"/> A check in the amount of \$1,888 00 cover the above fees is enclosed b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees A duplicate copy of this sheet is enclosed c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-1090 A duplicate copy of this sheet is enclosed d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING Information on this form may become public Credit card information should not be included on this form Provide credit card information and authorization on PTO-2038 NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: Karl R. Hermanns, Esq Seed Intellectual Property Law Group PLLC 701 5 th Avenue, Suite 6300 Seattle, WA 98104-7092 United States of America (206) 622-4900		
SIGNATURE <u>Karl R. Hermanns</u> NAME <u>33,507</u> REGISTRATION NUMBER		

ANTIVIRAL AGENTS

This invention relates to antiviral agents, in particular to compounds useful in the treatment of infections caused by Picornaviridae, such as human rhinovirus (HRV) and methods for
5 their preparation. The invention also relates to the use of these compounds in the treatment of picornavirus infections and to intermediates useful in the preparation of these compounds. The compounds of the invention are especially suitable for use in the treatment of HRV and accordingly it will be convenient to describe the invention in connection with these viruses. However it is to be understood that the invention is also
10 applicable to other viruses of the Picornavirus family.

Human rhinovirus are a member of the genus *Rhinovirus* of the picornavirus family and are believed to be responsible for between 40 and 50% of common cold infections. Human rhinoviruses comprise a group of over 100 serotypically distinct viruses and accordingly
15 antiviral activity for multiple serotypes and potency are considered to be equally important factors in drug design.

Two cellular receptors have been identified to which almost all typed HRVs bind. The major group, which comprises 91 of the more than 100 typed serotypes, binds to the
20 intracellular adhesion molecule-1 (ICAM-1) while the minor group, which comprises the rest of typed serotypes with the exception of HRV87, binds to the low density lipoprotein receptor family of proteins.

Another genus of the Picornaviridae family is represented by the Enteroviruses. This genus
25 includes polioviruses 1-3, coxsackieviruses A (23 serotypes) and B(6 serotypes), echoviruses (31 serotypes) and numbered enteroviruses 68-71. The clinical syndromes caused by enteroviruses include poliomyelitis, meningitis, encephalitis, pleurodynia, herpangina, hand foot and mouth disease, conjunctivitis, myocarditis and neonatal diseases such as respiratory illnesses and febrile illnesses.

- 2 -

Viruses of the Picornavirus family are characterised by a single stranded (+) RNA genome encapsidated by a protein shell (or capsid) having pseudo icosahedral symmetry. The surface of the capsid contains "canyons" which surround each of the icosahedral fivefold axes and it is believed that the cellular receptors bind to residues on the canyon floor.

5

A hydrophobic pocket lies underneath the canyon within which a number of antiviral compounds are capable of binding, sometimes with consequential conformational changes. Some of these compounds have been shown to inhibit the uncoating of HRVs and, for some of the major receptor group viruses, inhibition of cell receptor binding has also been demonstrated. It has also been shown that when a compound is bound within the hydrophobic capsid pocket, HRVs are more stable to denaturation by heat or acids.

10


Examples of antipicornoviral compounds believed to act by binding within the hydrophobic pockets of the picornavirus capsid are described in US Patents 4,992,433, 5,100,893, 5,070,090 and Australian Patent No. 628172. One compound which has been the subject of recent human clinical trials is ethyl 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]-ethoxy]benzoate, otherwise known as "Pirodavar". ("Intranasal Pirodavar (R77,975) Treatment of Rhinovirus Colds" F.G. Hayden, et al., *Antimicrobial Agents and Chemotherapy*, 39, 290-294, 1995).

20

A novel class of antiviral compounds has now been discovered which has been found to exhibit particularly favourable antipicornoviral properties.

Accordingly the present invention provides a compound of formula I

25







its salts, and pharmaceutically acceptable derivatives thereof where

Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical;

30

A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C₂₋₄alkylene radical, m and n are each

- 4 -

independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen or C₁₋₆alkyl; and

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

Alk is C₁₋₇alkylene or a direct bond;

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar.


The oxime ether compounds of the present invention may be in cis or trans form, or a mixture of these forms.

- 5 -

As used herein the term "aryl" refers to aromatic rings or ring systems. The aromatic rings may be carbocyclic, heterocyclic or pseudo aromatic, and may be mono- or bi-cyclic ring systems. The aromatic rings or ring systems are generally composed of 5 to 10 carbon atoms and, in the case of heteroaromatic rings, may contain one or more heteroatoms

- 5 selected from N, S and O. Examples of suitable aryl groups include but are not limited to phenyl, biphenyl, naphthyl, tetrahydronaphthyl, pyridinyl, thiophenyl, benzothiophenyl, furyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indolizinyl, isoindolyl, purinyl, oxazolyl, thiazolyl, isothiazolyl, isooxazolyl, triazinyl, triazolyl, tetrazolyl and the like, each of which may be optionally substituted with
- 10 C₁₋₆alkyl, C₁₋₆alkoxy, C₃₋₆alkynyl, C₃₋₆alkynyl, halo, hydroxy, mercapto, trifluoromethyl, amino, cyano or mono or di(C₁₋₆alkyl) amino. The term "pseudoaromatic" refers to a ring system which is not strictly aromatic, but which is stabilized by means of delocalization of electrons and behaves in a similar manner to aromatic rings. Examples of pseudoaromatic rings include but are not limited to furan, thiophene, pyrrole and the like.

- 15 Preferred aryl groups include phenyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1,2,4-triazinyl, furyl, thiophenyl thiazolyl, isothiazolyl, isoxazolyl, 1,2,4-triazolyl, oxazolyl, imidazolyl, pyrazolyl, 1,4-benzothiazinyl, indolyl and benzofuranyl. Particular examples of bivalent monocyclic and bicyclic aryl radicals are radicals of formula (c-1) to (c-6)
- 20 below:




(c-1)



(c-2)


- 6 -



(c-3)



(c-4)



(c-5)



(c-6)

where Y is as defined above; and




- 10 R^{10} and R^{11} are each independently hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, halo, amino, cyano, nitro, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylthio, or trifluoromethyl.

- Examples of Ar groups in combination with 5- or 6-membered rings formed by X^2 with the neighbouring carbon atom of Ar include indanones, tetralones, benzofuranones and
15 benzopyranones.



- The term "heterocyclic radical" as used herein refers to mono or bicyclic rings or ring systems which include one or more heteroatoms selected from N, S and O. The rings or ring systems generally include 1 to 14 carbon atoms in addition to the heteroatom(s) and
20 may be saturated, unsaturated, aromatic or pseudoaromatic.

Examples of 5-membered monocyclic heterocycles include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl,

oxadiazolyl, thiadiazolyl and examples of 6-membered monocyclic heterocycles include
 pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl. Examples of 9 and 10-
 membered bicyclic heterocycles include indolyl, benzofuranyl, benzothienyl,
 benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, isoquinolinyl,
 5 quinolinyl, quinoxaliny, cinnoliny, phthalazinyl, quinazolinyl, benzotriazinyl and the like.
 Examples of preferred heterocyclic ring systems include (optionally substituted)
 isoxazoles, isothiazoles, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles, 1,2,4-oxadiazoles, 1,2,4-
 thiadiazoles, oxazoles, thiazoles, pyridines, pyridazines, pyrimidines, pyrazines, 1,3,5-
 triazines, benzoxazoles, benzothiazoles, benzisoxazoles, benzisothiazoles, quinolines and
 10 quinoxalines. Particular examples of the group Het are radicals of formula (a-1) to (a-14)
 below:



- 8 -




5




10



15



- 9 -



(a-14)

wherein R¹ is hydrogen, C₁₋₆ alkyl, halo, hydroxy, mercapto, haloC₁₋₆alkyl, amino, mono or di(C₁₋₆alkyl)amino, cyano, formyl, C₁₋₆alkoxy, hydroxyC₁₋₄ alkyl, C₁₋₄alkoxyC₁₋₄ alkyl, C₁₋₆haloalkoxy, aryloxy, C₁₋₆alkylthio, arylthio, C₁₋₆alkylsulphinyl, C₁₋₆alkylsulphonyl, arylsulphinyl, arylsulphonyl, -CH=NO-C₁₋₄alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyl or aryl;

R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo or, in radicals (a-1), (a-4), (a-7) and (a-13), R¹ and R², or R² and R³ combined may represent a bivalent radical of formula -CH=CH-CH=CH- or (CH₂)_p where p is an integer from 2 to 4;

Y is O or S; and

Y' is O, S, SO or SO₂.

In some preferred embodiments of the invention one or more of the following definitions apply:

Het is a radical of formula (a-1), (a-2) or (a-8);

R¹ is hydrogen, methyl, ethyl, chloro, methoxy or trifluoromethyl;

R² and R³ are each independently hydrogen, chloro or methyl;

Y is O or S;

A is O, NH, NMe, a bond, or a radical of formula (b-1);

- 10 -

Z is CH or N;

Alk is C₁₋₆alkylene or a direct bond;

5

W is O;

Ar is a radical of formula (c-1), (c-2) or (c-4);

10 R¹⁰ and R¹¹ are each independently H, methyl, chloro, hydroxy, methoxy, cyano or nitro;

X¹ is C₁₋₄alkyl, C₂₋₄alkoxyalkyl, C₃₋₄alkenyl, C₃₋₄alkynyl, C₁₋₄haloalkyl, C₃₋₄haloalkenyl, C₃₋₄haloalkynyl or cyanomethyl;

15 X² is H, methyl or a bivalent radical of formula (CH₂)₂ or (CH₂)₃ which forms a 5- or 6-membered ring with the Ar group.

As used herein the term "C₁₋₆alkyl" as used alone or as part of a group such as "di(C₁₋₆alkyl)amino" refers to straight chain, branched or cyclic alkyl groups having from 1
20 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, cyclopentyl and cyclohexyl. Similarly C₁₋₄ alkyl refers to such groups having from 1 to 4 carbon atoms.

As used herein the term "halo" as used alone or as part of a group such as "C₃₋₆halo alkenyl" refers to fluoro, chloro, bromo and iodo groups.
25

As used herein the terms "C₁₋₆alkoxy" and "C₁₋₆alkyloxy" refer to straight chain or branched alkoxy groups having from 1 to 6 carbon atoms. Examples of C₁₋₆alkoxy include methoxy, ethoxy, *n*-propoxy, isopropoxy, and the different butoxy isomers.

30


As used herein the term "C₃₋₆alkenyl" refers to groups formed from C₃₋₆ straight chain, branched or cyclic alkenes. Examples of C₃₋₆alkenyl include allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl and 1,4-cyclohexadienyl.

As used herein the term "C₃₋₆alkynyl" refers to groups formed from C₃₋₆ straight chain or branched groups as previously defined which contain a triple bond. Examples of C₃₋₆alkynyl include 2,3-propynyl and 2,3- or 3,4-butylnyl.

The term "optionally substituted" as used herein means that a group may include one or more substituents which do not interfere with the binding activity of the compound of formula I. In some instances the substituent may be selected to improve binding.

Examples of optional substituents include halo, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkyl, hydroxy, aryl, amino, cyano, mercapto, C₁₋₄alkylamino, C₁₋₄dialkylamino, aryloxy, formyl, C₁₋₄alkylcarbonyl and C₁₋₄alkoxycarbonyl.

A particular group of compounds of the invention has the formula II:



wherein:

- 12 -

R¹ is hydrogen, C₁₋₄alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄ alkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy, aryloxy, C₁₋₄alkylthio, or aryl;

5 Z is CH or N;

Alk is C₁₋₆alkylene;


R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

10

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

15 X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

Another particular set of compounds of the invention have the formula III:



20

III

wherein:

R¹ is hydrogen, C₁₋₄alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy, 25 aryloxy, C₁₋₄alkylthio, or aryl;

A is a bond or CH₂O;

- 13 -


Alk is C₁₋₆alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

- 5 X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

- X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂-
 10 forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

A particular group of compounds of the invention has the formula IV



15

wherein:

R¹ is hydrogen, C₁₋₄ alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy, aryloxy, C₁₋₄alkylthio, or aryl;

20

Z is CH or N;

Alk is C₁₋₆alkylene;


- 25 R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

- 14 -

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

- 5 X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

A particular group of compounds of the invention has the formula V



- 10 wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxalinyl, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

- 15 Z is CH or N;

Alk is C₁₋₆alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;


- 20

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

- 25 X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

- 15 -

Another group of compounds of the invention has the formula VI



5 wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxalinyl, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

10 A is a direct bond, O, NH or NMe;

Alk is C₁₋₆ alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

15

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and


20 X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

Examples of specific compounds within the scope of the present invention are shown in Tables 1 to 8 below.

25

- 16 -

Table 1




5

Compd Number	R ¹	n	R ¹⁰ , R ¹¹	X ¹	X ²
1	Cl	2	H	CH ₂ CH ₃	H
2	Me	2	H	CH ₂ CH ₃	H
3	Cl	2	H	CH ₂ CH ₃	CH ₃
4	Me	2	H	CH ₂ CH ₃	CH ₃
5	Cl	2	2-(OMe)	CH ₂ CH ₃	H
6	Cl	2	2,6-(OMe) ₂	CH ₂ CH ₃	CH ₃
7	Me	2	H	CH ₃	H
8	Cl	2	H	CH ₃	H
9	Me	2	H	CH ₃	CH ₃
10	Cl	2	H	CH ₃	CH ₂ CH ₃
11	Cl	2	H	CH ₂ CH ₂ CH ₃	H
12	Cl	2	H	CH(CH ₃) ₂	H
13	Cl	2	H	CH ₂ CH=CH ₂	H
14	Cl	2	H	CH ₂ CN	H
15	Cl	2	H	CH ₂ C ₆ H ₅	H
18	Cl	2	2,6-(Me) ₂	CH ₃	H
19	Cl	2	2-(OMe)	CH ₃	CH ₃
20	Cl	2	H	(CH ₂ CH ₂ O) ₂ CH ₂ CH ₃	H
21	CF ₃ CH ₂ O	2	H	CH ₂ CH ₃	H
26	CH ₃ O	2	H	CH ₂ CH ₃	H
29	Cl	1	H	CH ₂ Phenyl	H
30	Cl	1	H	CH ₂ CH=CH ₂	H
31	Cl	1	H	CH ₂ CH ₃	H
32	Cl	3	H	CH ₂ CH ₃	H
33	Cl	2	2-(OMe)	CH ₃	H
34	Cl	2	H	CH ₂ CH ₃	CH ₂ CH ₃
35	Cl	2	H	CH ₂ CH=CH ₂	CH ₂ CH ₃
36	Cl	2	2-NO ₂	CH ₂ CH ₃	H
37	Cl	2	3-OH	CH ₂ CH ₃	H
42	Cl	2	2-Me	CH ₂ CH ₃	H
43	Cl	2	2-Me	CH ₂ CH=CH ₂	H

44	Cl	2	2-Me	CH ₃	H
45	Cl	2	2,6-(Me) ₂	CH ₂ CH ₃	H
49	H	2	H	CH ₂ CH ₃	H
50	Cl	2	3-OMe	CH ₂ CH ₃	H
51	Me	2	2-Me	CH ₂ CH ₃	H
52	Me	2	2-Me	CH ₃	H
53	Me	2	2-Me	CH ₂ CH=CH ₂	H
54	Me	2	2-Me	CH ₂ CH ₂ CH ₃	H
55	Cl	0	H	CH ₂ CH ₃	H
56	Phenyl	2	H	CH ₂ CH ₃	H
57	Cl	2	H	CH ₂ CH ₃ (cis isomer)	H
58	CF ₃	2	H	CH ₂ CH ₃	H
59	Me	2	H	CH ₂ CF ₃	H
63	MeO	2	H	CH ₂ CH=CH ₂	H
85	Me	2	H	CH ₂ CH ₂ CH ₃	H
86	Me	2	H	CH ₂ CH ₂ OCH ₃	H
87	Me	2	H	CH ₂ CH=CH ₂	H
88	Me	2	H	CH ₂ C=CH	H
89	Cl	3	H	CH ₃	H
90	Cl	3	H	CH ₂ CH=CH ₂	H
94	Me	3	H	CH ₃	H
95	Me	3	H	CH ₂ CH ₃	H
96	Me	3	H	CH ₂ CH=CH ₂	H
100	CF ₃	3	H	CH ₃	H
102	H	3	H	CH ₃	H
103	H	3	H	CH ₂ CH ₃	H
104	H	3	H	CH ₂ CH=CH ₂	H
128	O=CH	2	H	CH ₂ CH ₃	H
129	HOCH ₂	2	H	CH ₂ CH ₃	H
143	Me	2	H	CH ₂ CH ₂ F	H
144	Me (Pyridazine N-oxide)	2	H	CH ₂ CH ₃	H
145	Me	2	H	CH ₂ CH ₃	H
146	Me	2	2-OH	CH ₂ CH ₃	H
185	Me	2	3,5-(Me) ₂	CH ₂ CH ₃	H
186	Me	2	3,5-(Me) ₂	CH ₃	H
187	Me	2	3-OMe	CH ₂ CH ₃	H
188	Me	2	3-Me	CH ₂ CH ₃	H
189	Me	2	3-Me	CH ₃	H
190	Me	2	2,5-(Me) ₂	CH ₂ CH ₃	H
191	Me	2	2,5-(Me) ₂	CH ₃	H
192	ME	2	2,3-(Me) ₂	CH ₂ CH ₃	H
193	Me	2	2,3-(Me) ₂	CH ₃	H
208	MeON=CH-	2	H	CH ₂ CH ₃	H

- 18 -

Table 2




5

Compound number	R ¹	n	R ¹⁰	X ¹	X ²
16	Cl	2	H	CH ₃	H
17	Cl	2	6-OMe	CH ₃	H
38	Cl	2	5-OH	CH ₃	H
39	Cl	2	5-OH	CH ₂ CH ₃	H
40	Cl	2	5-OH	CH ₂ CH=CH ₂	H
41	Cl	2	H	CH ₂ CH ₃	H
46	Me	2	H	CH ₂ CH ₃	H
47	Me	2	H	CH ₂ CH=CH ₂	H
48	Me	2	H	CH ₃	H
60	Cl	1	H	CH ₃	H
61	Cl	1	H	CH ₂ CH ₃	H
62	Cl	1	H	CH ₂ CH=CH ₂	H
91	Cl	3	H	CH ₃	H
92	Cl	3	H	CH ₂ CH ₃	H
93	Cl	3	H	CH ₂ CH=CH ₂	H
97	Me	3	H	CH ₃	H
98	Me	3	H	CH ₂ CH ₃	H
99	Me	3	H	CH ₂ CH=CH ₂	H
101	CF ₃	3	H	CH ₃	H
105	H	3	H	CH ₃	H
106	H	3	H	CH ₂ CH ₃	H
107	H	3	H	CH ₂ CH=CH ₂	H
213	Me	2	H	CH ₂ CH ₃	-CH ₂ -CH ₂ - (2-position)

- 19 -


Table 3



Compd number	R ¹	n	R ¹⁰ , R ¹¹	X ¹	X ²
22	Me	3	2,6-(Me) ₂	CH ₃	H
23	Me	3	2,6-(Me) ₂	CH ₂ CH=CH ₂	H
24	Me	3	2,6-(Me) ₂	CH ₂ CH ₃	H
25	Me	3	2,6-(Me) ₂	CH ₂ C ₆ H ₅	H
108	Me	3	H	CH ₂ CH ₃	H
109	Me	3	2,6-(Me) ₂	CH ₃	Me
110	Me	3	2,6-(Me) ₂	CH ₂ CH=CH ₂	Me
111	Me	3	2,6-(Me) ₂	CH ₂ CH=CH ₂ (cis-isomer)	Me
112	Me	3	2,6-(Me) ₂	CH ₂ CH ₂ CH ₃	H
113	Me	3	2,6-(Me) ₂	CH ₃	Et
114	Me	3	2,6-(Me) ₂	CH ₂ CH ₃	Et
115	Me	3	2,6-(Me) ₂	CH ₂ CH=CH ₂	Et
116	Me	3	2,6-(Me) ₂	CH ₂ CH ₃	Me
117	Me	3	2,6-(Me) ₂	CH(CH ₃) ₂	H
118	Me	3	2,6-(Me) ₂	CH ₂ CN	H
119	Me	3	2,6-(Me) ₂	CH ₂ C=CH	H
120	Me	6	2,6-(Me) ₂	CH ₂ CH ₃	H
121	Me	7	2,6-(Me) ₂	CH ₂ CH ₃	H
122	Me	5	2,6-(Me) ₂	CH ₂ CH ₃	H
123	Me	4	2,6-(Me) ₂	CH ₂ CH ₃	H
124	Me	3	2,6-(Me) ₂	CH ₂ CF ₃	H
125	Me	3	2,6-(Me) ₂	CH ₂ CH ₂ OCH ₂ CH ₃	H
126	Me	3	2,6-(Me) ₂	CH ₂ COCH ₃	H
127	Phenyl	3	2,6-(Me) ₂	CH ₂ CH ₃	H
130	Et	3	2,6-(Me) ₂	CH ₂ CH ₃	H
131	n-Pr	3	2,6-(Me) ₂	CH ₂ CH ₃	H
132	Et	2	2,6-(Me) ₂	CH ₂ CH ₃	H
133	n-Pr	2	2,6-(Me) ₂	CH ₂ CH ₃	H
134	Me	3	2,6-(Me) ₂	CH ₂ CH ₂ F	H
137	Cyclopropyl	3	2,6-(Me) ₂	CH ₂ CH ₃	H
138	Et	4	2,6-(Me) ₂	CH ₂ CH ₃	H
139	nPr	4	2,6-(Me) ₂	CH ₂ CH ₃	H

- 20 -

Table 4



5


Compd No.	R ¹	Position of Oxime ether on phenyl ring	X ¹	X ²
27	Cl	4	CH ₂ CH ₃	H
64	H	4	CH ₂ CH ₃	H
65	H	3	CH ₂ CH ₃	H
66	H	4	CH ₂ CH=CH ₂	H
67	Me	4	CH ₃	H
68	Me	4	CH ₂ CH ₃	H
69	Me	4	CH ₂ CH=CH ₂	H
70	Me	3	CH ₃	H
71	Me	3	CH ₂ CH ₃	H
72	Me	3	CH ₂ CH=CH ₂	H
73	Cl	4	CH ₃	H
74	Cl	4	CH ₂ CH=CH ₂	H
75	Cl	3	CH ₃	H
76	Cl	3	CH ₂ CH ₃	H
77	Cl	3	CH ₂ CH=CH ₂	H
78	CF ₃	4	CH ₃	H
79	CF ₃	4	CH ₂ CH ₃	H
80	CF ₃	4	CH ₂ CH=CH ₂	H
81	CF ₃	3	CH ₃	H
82	CF ₃	3	CH ₂ CH ₃	H
83	CF ₃	3	CH ₂ CH=CH ₂	H
135	Me	4	CH ₂ CH ₂ CH ₃	H
136	Me	3	CH ₂ CH ₂ CH ₃	H
148	Cl	4	CH ₂ CH ₂ CH ₃	H
149	Cl	3	CH ₂ CH ₂ CH ₃	H

10

15

- 21 -


Table 5



Compd No	R ¹	n	Position of Oxime ether on Phenyl ring	X ¹
28	Cl	1	4	CH ₂ CH ₃
140	Cl	2	4	CH ₃
141	Cl	2	4	Allyl
142	Cl	2	4	Ethyl
150	Cl	3	4	Ethyl
151	Cl	3	4	Allyl
164	CF ₃	3	4	Methyl
165	CF ₃	3	4	Ethyl
166	CF ₃	3	4	Allyl
167	CF ₃	3	3	Methyl
168	CF ₃	3	3	Ethyl
169	CF ₃	3	3	Allyl
170	Me	3	4	Allyl
171	Me	3	3	Methyl
172	Me	3	3	Ethyl
173	Me	3	3	Allyl
174	Cl	1	4	Methyl
175	Cl	1	4	Allyl
176	Cl	1	3	Methyl
177	Cl	1	3	Ethyl
178	Cl	1	3	Allyl
179	CF ₃	1	4	Methyl
180	CF ₃	1	4	Ethyl
181	CF ₃	1	4	Allyl
182	CF ₃	1	3	Methyl
183	CF ₃	1	3	Ethyl
184	CF ₃	1	3	Allyl


- 22 -

Table 6



Compound No	Het	Z	X ¹
84	5-CF ₃ -2-Pyridyl	CH	Ethyl
152	5-Chloro-2-Pyrazinyl	N	Ethyl
153	5-CF ₃ -1,3,4-thiadiazol-2-yl	CH	Methyl
154	5-CF ₃ -1,3,4-thiadiazol-2-yl	CH	Ethyl
157	5-Methyl-1,3,4-thiadiazol-2-yl	CH	Methyl
158	5-Methyl-1,3,4-thiadiazol-2-yl	CH	Ethyl
159	5-Chloro-2-Pyrazinyl	CH	Methyl
160	5-Chloro-2-Pyrazinyl	CH	Ethyl
196	6-Methyl-2-Pyridyl	CH	Ethyl
197	4-EtO ₂ C-Thiazol-2-yl	CH	Methyl
198	4-Ethoxycarbonyl-2-Thiazolyl	CH	Ethyl
199	6-Chloro-2-Pyrazinyl	CH	Methyl
200	Benzoxazol-2-yl	CH	Methyl
201	Benzoxazol-2-yl	CH	Ethyl
202	4,6-Dimethoxy-1,3,5-Triazin-2-yl	CH	Methyl
203	4,6-Dimethoxy-1,3,5-Triazin-2-yl	CH	Ethyl
204	5-Ethyl-2-Pyrimidin-2-yl	CH	Methyl
205	5-Ethyl-2-Pyrimidin-2-yl	CH	Ethyl
206	Benzothiazol-2-yl	CH	Methyl
207	Benzothiazol-2-yl	CH	Ethyl
210	6-Chloro-2-quinoxalanyl	CH	Ethyl
212	6-Chloro-5-Methyl-3-Pyridazinyl	CH	Ethyl


Table 7



Compd No	Het	A	n	X ¹
147	6-Cl-3-Pyridazinyl	NH	5	Ethyl
161	6-Cl-3-Pyridazinyl	NMe	5	Ethyl
162	6-Cl-3-Pyridazinyl	NH	6	Ethyl
163	6-Cl-3-Pyridazinyl	NH	4	Ethyl
194	6-Cl-3-Pyridazinyl	NMe	6	Methyl
195	6-Cl-3-Pyridazinyl	NMe	4	Ethyl
209	6-Cl-3-Pyridazinyl	O	5	Ethyl
211	6-Cl-2-Quinoxaliny	Direct bond	0	Ethyl

5

Table 8




10

Compound No	R ¹	n	X ¹
155	Me	2	Ethyl
156	Me	2	Methyl

The compounds of the present invention may be prepared using methods analogous to those described in the prior art. For example, compounds in which the Het radical is of formula (a-1) may be prepared using methodology analogous to the processes described in US Patents 4,992,433, 5,112,825 and 5,100,893. Similarly, compounds in which Het is (a-2), (a-3), (a-4), (a-5) or (a-6) may be prepared using methodology similar to that described in US Patent 5,070,090 and Australian patent No. 629172, and compounds in which Het is (a-7) or (a-8) may be prepared in accordance with methodology similar to that described in US Patent 5,364,865.

20


In one method the compounds of the present invention are prepared via an intermediate of formula VII:



VII

where A, Alk, W, Ar and X^2 are as described above, and X^3 is X^1 or an oxime protecting group.

This intermediate may be prepared using methodology similar to that described in US Patent 5,231,184. In one example intermediates of formula VII, when W is O, are prepared by the reaction of compounds of the formula P-A-Alk-OH or P-A-Alk-L with hydroxy aromatic compounds of formula VIII.



VIII

where Ar, X^1 , X^2 and X^3 are as defined above, P is H or a protecting group, and L is a leaving group. Removal of the protecting group P in the reaction product affords the reactive intermediates of formula VII.


Examples of suitable protecting groups P in compounds of formula P-A-Alk-OH or P-A-Alk-L include benzyl or acyl moieties which can be introduced and removed by standard methods (see "Protective Groups in Organic Synthesis" Theodora Green, Wiley Interscience, 1981).

The intermediate of formula VII may be reacted with a compound of formula Het-L, where Het is as defined above and L is a suitable leaving group, optionally followed by deprotection and/or conversion of X^3 to X^1 , to afford a compound of formula I. This N-alkylation reaction can be conducted using procedures known to the art, such as under the conditions described in US Patent 5,231,184 for performing analogous N-alkylations.

The intermediates of formula VII are novel and represent a further aspect of the present invention.


Examples of suitable leaving groups include halogen, such as fluoro, chloro, bromo and iodo, and halogen-like groups such as p-toluenesulphonyloxy and methanesulphonyloxy.

Another method for the preparation of the compounds of formula I involves the addition of an alkoxyamine H_2NOX^1 to an aldehyde or ketone of formula IX




where Het, A, Alk, W, Ar X^1 and X^2 are as defined for formula I above. This reaction is carried out using standard conditions, such as in an aqueous or alcoholic solvent at ambient temperature or with warming.

15 A further method of forming the compounds of the invention involves reaction of a carbonyl compound of formula IX with hydroxylamine to give of an oxime of formula X,



which is then O-alkylated with a compound $L-X^1$, where L is a leaving group and X^1 is as defined for formula I.

25 An additional method of preparing certain compounds of the invention of formula Ia (Compounds for formula I where $W = O$) involves condensing an oxime ether of formula XI with a suitable precursor of formula (XII)



using Mitsunobu Reaction conditions (see Chemical Syntheses, Vol. 42, p 335, 1992) and where Het, A, Alk, Ar, X¹ and X² are as defined for formula I.

- 5 Methods for the preparation of intermediate carbonyl compounds of formulae IX have been described in the chemical literature (US Patents 4,992,433, 4,451,476). Compounds of formula XI are well known in the chemical literature (eg German Patent DE 3,601,564). Several references, including US Patents 5,112,825 and 5,242,924 describe methods for the preparation of various compounds of formula XII.

- 10 The compounds of the present invention are useful in the prevention or treatment of picornoviral infections in mammals, particularly humans.

- Accordingly in a further aspect the invention provides a method for the treatment or prophylaxis of a picornaviral infection in a mammal including the step of administering
15 an effective amount of a compound of formula I.

- The picornavirus infection may be caused by any virus of the family Picornaviridae. Representative family members include human rhinoviruses, polioviruses, enteroviruses including coxsackieviruses and echoviruses, hepatovirus, cardioviruses, aphthovirus,
20 hepatitis A and other picornaviruses not yet assigned to a particular genus, including one or more of the serotypes of these viruses. Preferably the invention is used in the prevention or treatment of infection caused by one or more serotypes of rhinovirus.

- Without wishing to be limited by theory it is believed that the oxime ether moiety of the
25 compound of formula I may be involved in hydrogen bonding with an asparagine residue generally present near the opening of the hydrophobic pocket and that this interaction enhances the binding of the compounds in the capsid pocket, relative to the prior art compounds. It is further believed that the oxime ether bond may be more resistant to hydrolysis and esterase activity than the ester bond of pirodavir, and that this may allow
30 more flexibility in the methods of administration of the compound to the site of activity, than available for readily hydrolysable pirodavir. In particular it may allow oral

administration of the compounds or reduce metabolism in the nasal mucosa following topical administration.

The salts of the compound of formula I are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts. The pharmaceutically acceptable salts may include conventional non-toxic salts or quaternary ammonium salts of these compounds, which may be formed, e.g. from organic or inorganic acids or bases. Examples of such acid addition salts include, but are not limited to, those formed with pharmaceutically acceptable acids such as acetic, propionic, citric, lactic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, ascorbic, hydrochloric, orthophosphoric, sulphuric and hydrobromic acids. Base salts includes, but is not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium magnesium, ammonium and alkylammonium. Also, basic nitrogen-containing groups may be quaternised with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.

The compounds of the invention may be in crystalline form or as solvates (e.g. hydrates) and it is intended that both forms are within the scope of the present invention. Methods of solvation are generally known within the art.

Pharmaceutically acceptable derivatives may include any pharmaceutically acceptable salt, hydrate or any other compound or prodrug which, upon administration to a subject, is capable of providing (directly or indirectly) a compound of formula I or an antivirally active metabolite or residue thereof.

Any compound that is a prodrug of a compound of formula I is within the scope and spirit of the invention. The term "pro-drug" is used in its broadest sense and encompasses those derivatives that are converted *in vivo* to the compounds of the invention. Such derivatives

- 28 -

would readily occur to those skilled in the art, and include, for example, compounds where a free hydroxy group is converted into an ester derivative or a ring nitrogen atom is converted to an N-oxide. Examples of ester derivatives include alkyl esters, phosphate esters and those formed from amino acids, preferably valine.

5

It will be appreciated that some derivatives of the compound of formula I may have an asymmetric centre, and therefore are capable of existing in more than one stereoisomeric form. The invention extends to each of these forms individually and to mixtures thereof, including racemates. The isomers may be separated conventionally by chromatographic methods or using a resolving agent. Alternatively the individual isomers may be prepared by asymmetric synthesis using chiral intermediates.

10

The invention also provides the use of a compound of formula I in the manufacture of a medicament for the treatment or prophylaxis of picornavirus infection.

15

While it is possible that, for use in therapy, a compound of the invention may be administered as the neat chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

20

In view of the general lipophilic nature of the compounds they are particularly suitable to oral forms of administration, however other forms of administration are also envisaged.

25

The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

30

The compounds of this invention may also be useful in combination with known anti-viral or anti-retroviral agents or other pharmaceuticals used in the treatment of viral infections.

- 29 -

Representative examples of these additional pharmaceuticals include immunomodulators, immunostimulants, antibiotics and anti-inflammatory agents. Exemplary anti-viral agents include zanamivir, rimantidine, amantidine, ribavirin, AZT, 3TC, (-) FTC, acyclovir, famciclovir, penciclovir, ddI, ddC, ganciclovir, saquinavir, loviride, other non-nucleotide reverse transcriptase (RT) inhibitors and protease inhibitors, antiviral and antireceptor antibodies and receptor analogues, such as ICAM-1. Exemplary immunomodulators and immunostimulants include various interleukins, cytokines and antibody preparations. Exemplary antibiotics includes antifungal agents and antibacterial agents. Exemplary anti-inflammatory agents include glucocorticoids and non-steroidal anti-inflammatory compounds.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to two hundred (200) milligrams, per tablet, are accordingly suitable representative unit dosage forms. The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.

- 5 A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

- 10 In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

- 15 The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with
- 20 encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
- 25 For preparing suppositories, a low melting wax, such as admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

- 5 Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

- 10 The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, 15 the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

- 20 Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

- 25 Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the 30 active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of
 5 suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising
 10 active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for
 15 example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising
 20 spray pump. To improve nasal delivery and retention the compounds according to the invention may be encapsulated with cyclodextrins, or formulated with their agents expected to enhance delivery and retention in the nasal mucosa.

Administration to the respiratory tract may also be achieved by means of an aerosol
 25 formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).

- 5 Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- 10 In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 1 to 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
- 15 When desired, formulations adapted to give sustained release of the active ingredient may be employed.


- The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active
- 20 component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
 - 25 Liquids or powders for intranasal administration, tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

- The invention will now be described with reference to the following examples which illustrate some preferred aspects of the present invention. However it is to be understood
- 30 that the particularity of the following description of the invention is not to supersede the generality of the preceding description of the invention.

EXAMPLES

Example 1

Preparation of 4-{2-[1-(6-Chloro-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde O-ethyloxime (Compound 1)




4-{2-[1-(6-Chloro-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde (Intermediate IIa) was prepared from 4-hydroxybenzaldehyde and 2-[1-(6-Chloro-3-pyridazinyl)-4-piperidinyl]ethanol using a Mitsunobu Reaction and following the general methods described in US Patent 4,992,433. The aldehyde (60mg, 0.17mmol) was dissolved in ethanol (5 ml) with stirring at room temperature and a solution of ethoxyamine in water (0.5 ml, 50% EtONH₂) was added. The reaction was stirred at room temperature for 2 days and then concentrated on a rotary evaporator and the residue was purified by chromatography (silica gel 18g) using chloroform as eluent. The first compound to elute was the O-ethyloxime (1) which was obtained as a pale cream solid (30mg, 44%).

¹H nmr spectrum (CDCl₃) δ (ppm): 1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.35 (bd, 2H); 6.87 (d, 2H); 6.90 (d, 1H); 7.16 (d, 1H); 7.52 (d, 2H); 8.02 (s, 1H).

Mass Spectrum (ESI) 389 (M+1)⁺

Example 2

Preparation of 4-{2-[1-(6-Methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde O-ethyloxime (Compound 2)



- (a) A solution of 4-hydroxybenzaldehyde (100mg, 0.88mmol) and 50% O-ethylhydroxylamine aqueous solution (0.6ml, 4.9mmol) in dioxane (2 ml) was stirred under an atmosphere of argon at room temperature for 16 hours and then heated at 90-100° for 3 hours when thin layer chromatography (silica, dichloromethane) indicated the reaction was complete. The solution was evaporated to dryness and the residue partitioned between ethyl acetate (20 ml) and water (5 ml). The organic layer was washed with water, dried (Na₂SO₄) and evaporated to afford 4-hydroxybenzaldehyde O-ethylloxime (125mg, 92.5%).
- (b) To a solution of 4-hydroxybenzaldehyde O-ethylloxime (49mg, 0.4mmol), 2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethanol (88mg, 0.4mmol) and triphenylphosphine (115mg, 0.44mmol) in dry tetrahydrofuran (THF) (5 ml) under argon at room temperature was added dropwise diisopropylazodicarboxylate (89mg, 0.44mmol) in dry THF. The resulting solution was stirred at 20° for 24 hours and the solvent was then removed on a rotary evaporator. The residue was chromatographed on silica gel, using firstly ethyl acetate/hexane (1:1) as eluent to give the product (Compound 2) as a white solid (103mg, 70%).
- ¹H nmr spectrum (CDCl₃) δ (ppm): 1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.53 (s, 3H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.35 (bd, 2H); 6.88 (d, 2H); 6.90 (d, 1H); 7.05 (d, 1H); 7.52 (d, 2H); 8.02 (s, 1H).
- Mass Spectrum (ESI) 369 (M+1)⁺

Example 3

- The Compound No's 5, 8, 11, 12, 13, 14, 15, 20, 21 and 22-25 from Tables 1 and 3 of the invention were prepared following essentially the same method as described in Example 1 for Compound 1, using the appropriate carbonyl compound (Het-A-Alkylene-O-Aryl-C(X²)=O and alkoxyamine (H₂NO-X¹). The compounds were purified by chromatography on silica gel and characterised by their nuclear magnetic resonance (nmr) spectra and Mass Spectral (MS) data. For convenience the nmr and MS data are recorded in Table 9 below.

Table 9

Compd Number	MS data (ESI)	NMR data: Proton Chemical Shift, δ in ppm (CDCl ₃)
5	419 (M+1)	1.20-1.40(m, 5H); 1.65-1.95(m, 5H); 3.0(bt, 2H); 3.89(s, 3H); 4.08(t, 2H); 4.21(q, 2H); 4.35(bd, 2H); 6.85(d, 1H); 6.92(d, 1H); 7.0(dd, 1H); 7.15(d, 2H); 7.24(d, 1H); 8.02(s, 1H)
8	375 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 3.93(s, 3H); 4.05(t, 2H); 4.40(d, 2H); 6.88(d, 2H); 7.0(d, 1H); 7.24(d, 1H); 7.51(d, 2H); 8.02(s, 1H)
11	403 (M+1)	0.95(t, 3H); 1.30(m, 2H); 1.65-1.95(m, 5H); 1.77(t, 2H); 2.95(t, 2H); 3.92-4.20(m, 4H); 4.35(d, 2H); 6.85(d, 2H); 6.90(d, 1H); 7.20(d, 1H); 7.50(d, 2H); 8.07(s, 1H)
12	403 (M+1)	1.25(d, 6H); 1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 4.05(t, 2H); 4.35(d, 2H); 4.42(m, 1H); 6.85(d, 2H); 6.90(d, 1H); 7.20(d, 1H); 7.51(d, 2H); 8.05(s, 1H)
13	401 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 4.05(t, 2H); 4.35(d, 2H); 4.66(d, 2H); 5.25(dd, 1H); 5.38(dd, 1H); 6.08(m, 1H); 6.85(d, 2H); 6.90(d, 1H); 7.20(d, 1H); 7.50(d, 2H); 8.13(s, 1H)
14	400 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 4.05(t, 2H); 4.35(d, 2H); 4.75(s, 2H); 6.85(d, 2H); 6.90(d, 1H); 7.20(d, 1H); 7.50(d, 2H); 8.07(s, 1H)
15	451 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 4.05(t, 2H); 4.35(d, 2H); 5.20(s, 2H); 6.85(d, 2H); 6.88(d, 1H); 7.20(d, 1H); 7.41(s, 5H); 7.50(d, 2H); 8.08(s, 1H)
20	Not recorded	1.15-1.45(m, 5H); 1.65-1.95(m, 5H); 2.95(bt, 2H); 3.50(q, 2H); 3.55-3.80(m, 6H); 4.05(t, 2H); 4.3(t, 4H); 4.36(d, 2H); 6.85(d, 2H); 6.90(d, 2H); 7.2(d, 1H); 7.45(d, 2H); 8.05(s, 1H)
21	Not recorded	1.15-1.45(m, 5H); 1.65-1.95(m, 5H); 3.0(bt, 2H); 4.05(t, 2H); 4.22(q, 2H); 4.30(bd, 2H); 4.83(q, 2H); 6.90(d, 2H); 7.04(d,

		1H); 7.20(d, 1H); 7.53(d, 2H); 8.05(s, 1H)
22	303 (M+1)	2.2(m, 2H); 2.26(2xs, 9H); 2.99(t, 2H); 3.81(t, 2H); 3.94(s, 3H); 5.87(s, 1H); 7.23(s, 2H); 7.95(s, 1H)
23	329 (M+1)	2.2(m, 2H); 2.26(2xs, 9H); 2.99(t, 2H); 3.81(t, 2H); 4.65(m, 2H); 5.2-5.4(m, 2H); 6.0-6.15(m, 1H); 5.87(s, 1H); 7.23(s, 2H); 8.01(s, 1H)
24	Not recorded	1.3(t, 3H); 2.2(m, 2H); 2.27(2xs, 9H); 2.99(t, 2H); 3.81(t, 2H); 4.18(q, 2H); 5.87(s, 1H); 7.23(s, 2H); 7.96(s, 1H)
25	401 (M+23)	2.2(m, 2H); 2.26(2xs, 9H); 2.99(t, 2H); 3.81(t, 2H); 5.19(s, 2H); 5.87(s, 1H); 7.23(s, 2H); 7.3-7.45(m, 5H); 8.04(s, 1H)

Example 4

- The Compound No's 3, 4, 6, 7, 9, 10, 16, 17, 18, 19 from Tables 1 and 2 of the invention were prepared using essentially the same method as described in Example 2 for Compound 2 and were obtained in yields of 61-73%. The compounds were purified by column chromatography on silica gel and characterised by their nuclear magnetic resonance (nmr) spectra and Mass Spectral (MS) data. For convenience the nmr and MS data are recorded in Table 10 below.

10


Table 10

Compound Number	MS data (ESI)	NMR data: Proton Chemical Shift, δ in ppm (CDCl ₃)
3	403 (M+1)	1.20-1.40(m, 5H); 1.65-1.95(m, 5H); 2.15(s, 3H); 2.95(t, 2H); 4.05(t, 2H); 4.23(q, 2H); 4.35(d, 2H); 6.85(d, 2H); 6.94(d, 1H); 7.18(d, 1H); 7.60(d, 2H)
4	383 (M+1)	1.20-1.40(m, 5H); 1.65-1.95(m, 5H); 2.15(s, 3H); 2.53(s, 3H); 2.95(t, 2H); 4.05(t, 2H); 4.18(q, 2H); 4.35(d, 2H); 6.89-6.90(2xd, 3H); 7.12(d, 1H); 7.61(d, 2H)
6	463 (M+1)	1.20-1.40(m, 5H); 1.65-1.95(m, 5H); 2.15(s, 3H); 2.95(t, 2H);

		3.90(s, 6H); 4.05(t, 2H); 4.22(q, 2H); 4.35(d, 2H); 6.85(s, 2H); 6.90(d, 1H); 7.14(d, 1H)
7	355 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.53(s, 3H); 2.95(t, 2H); 3.93(s, 3H); 4.05(t, 2H); 4.35(d, 2H); 6.88(d, 2H); 6.90(d, 1H); 7.05(d, 1H); 7.51(d, 2H); 8.05(s, 1H)
9	369 (M+1)	1.32(m, 2H); 1.65-1.95(m, 5H); 2.15(s, 3H); 2.49(s, 3H); 2.95(t, 2H); 3.93(s, 3H); 4.06(t, 2H); 4.35(d, 2H); 6.88(d, 2H); 7.15(d, 1H); 7.25(d, 1H); 7.55(d, 2H)
10	403 (M+1)	1.02-1.40(m, 5H); 1.65-1.95(m, 5H); 2.70(q, 2H); 2.95(t, 2H); 3.91(s, 3H); 4.05(t, 2H); 4.35(d, 2H); 6.82(d, 2H); 6.88(d, 1H); 7.15(d, 1H); 7.55(d, 2H)
16	375 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 3.93(s, 3H); 4.03(t, 2H); 4.35(d, 2H); 6.85(d, 2H); 7.03(d, 1H); 7.12(d, 1H); 7.18(d, 1H); 7.28(d, 1H); 8.03(s, 1H)
17	405 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.95(t, 2H); 3.85(s, 3H); 3.93(s, 3H); 4.15(t, 2H); 4.35(d, 2H); 6.85(d, 1H); 6.90(d, 1H); 6.98(dd, 1H); 7.16(d, 1H); 7.23(d, 1H); 8.0(s, 1H)
18	403 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.25(s, 6H); 3.0(t, 2H); 3.85(t, 2H); 3.91(s, 3H); 4.35(d, 2H); 6.92(d, 1H); 7.10(d, 1H); 7.26(s, 2H); 8.0(s, 1H)
19	419 (M+1)	1.30(m, 2H); 1.65-1.95(m, 5H); 2.15(s, 3H); 2.95(t, 2H); 3.90(s, 3H); 3.95(s, 3H); 4.07(t, 2H); 4.35(d, 2H); 6.82(d, 1H); 6.90(d, 1H); 6.99(dd, 1H); 7.14(d, 1H); 7.26(d, 1H)

Example 5**Preparation of 3,5-Dimethyl-4-{3-(3-Phenyl-5-isoxazoly)propoxy}benzaldehyde O-ethyloxime (Compound 127)**

5



- 10 (a) Condensation of 4-pentyn-1-ol and 4-hydroxy-3,5-dimethylbenzaldehyde O-ethyloxime using Mitsunobu Reaction conditions (see for example J. Med. Chem., **36**, 3240, 1993 and references cited therein) gave 3,5-dimethyl-4-(4-pentyn-1-yloxy)benzaldehyde O-ethyl oxime in good yield.

(b) Isoxazole ring formation (also see J. Med. Chem., **38**, 1355, 1995)


- 15 A solution of benzaldehyde oxime (45 mg, 0.372 mmol) in DMF (0.5 ml) was added dropwise to a solution of N-chlorosuccinimide (50mg, 0.374mmol) and pyridine (1 drop) in DMF (0.5 ml), keeping the temperature between 25-30°C. The resulting solution was allowed to stir at room temperature for 90 minutes. To this was added a solution of 3,5-dimethyl-4-(4-pentyn-1-yloxy)benzaldehyde O-ethyl oxime (49mg, 0.189mmol) in DMF
- 20 (0.5mL, the resulting solution was then heated at 85-90°C for 10 minutes. To this was added, dropwise over 10 minutes, a solution of triethylamine (54μl, 0.386mmol) in DMF (0.5 ml), the resulting solution was then heated at 85-90°C for 1 hour. The reaction was cooled and the solvent removed *in vacuo*. The residue was partitioned between ethyl acetate (50 ml) and water (15 ml). The organic phase was washed with brine (15mL), dried
- 25 (MgSO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography (Ethyl acetate/Hexane 5%) gave the product (Compound 127) as a clear oil (23mg, 32 %). The structure was confirmed by the ¹H nmr spectrum which is given in Table 11 below.

Example 6

The Compound No's 130, 131, 132, 133, 137, 138, and 139 from Table 3 of the invention were prepared using the appropriate oxime and essentially the same method as described in Example 5 for Compound 127. The compounds were purified by column chromatography on silica gel and characterised by their nuclear magnetic resonance (nmr) spectra and Mass Spectral (MS) data which are summarised in Table 11 below.

Example 7

Preparation of 2-(1-(6-methyl-3-pyridazinyl)-4-piperidinyloxy)-thiazole-4-carboxaldehyde O-ethyl oxime (Compound No. 155)



- 15 (a) Sodium borohydride (690mg, 18mmol) was added as a single portion to a solution of ethyl 2-chloro-4-thiazolecarboxylate (1.6g, 9mmol) in ethanol (70ml) at 0°C, then the mix was allowed to warm to room temperature with stirring overnight. The reaction was acidified to pH 5 with 1N HCl and concentrated under vacuum, then the white residue was partitioned between water (125ml) and ethyl acetate (3x300ml). The organic phase was
- 20 washed with brine and dried (Na₂SO₄), then the solvents were removed. Chromatography of the residue on silica gel (15g, eluent 15%-30% hexane/ethyl acetate) gave 2-chloro-4-hydroxymethylthiazole (850mg, 5.5mmol) in 63% yield as a clear oil, ¹H nmr; 4.72 (s, 2H), 7.11 (s, 1H).
- 25 (b) Tert-butyldimethylsilylchloride (1.07g, 7.1mmol) was added as a single portion to a solution of the hydroxymethylthiazole (840mg, 5.6mmol) and imidazole (500mg, 7.34mmol) in anhydrous DMF (20ml). The solution was stirred overnight under an argon atmosphere. Solvents were removed under vacuum and the residue was partitioned between water (100ml) and ethyl acetate (500ml). The organic layer was washed with
- 30 brine, dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica gel (200g; eluent 5%-50%DCM/hexane) to give 2-chloro-4-t-

butyldimethylsilyloxymethylthiazole (1.29g, 4.9mmol) in 87% yield, ¹H nmr 0.11 (s, 6H), 0.94 (s, 9H), 4.78 (s, 2H), 7.08 (s, 1H).

- (c) A suspension of sodium hydride (60%, 135mg, 3.4mmol) and 1-(6-methyl-3-pyridazinyl)-4-(2-hydroxyethyl)-piperidine (250mg, 1.1mmol) in dimethoxyethane (DME; 4ml) was stirred at room temperature for 2hr. A solution of 2-chloro-4-t-butylidimethylsilyloxymethylthiazole (385mg, 1.46mmol) in DME (1ml) was added and the mixture stirred at reflux under argon for 5hr then at room temperature overnight. The mixture was diluted with ether, filtered and then concentrated. The residue was chromatographed on silica gel (25g; eluent 30%-50% ethyl acetate/hexane) to give 2-(1-(6-methyl-3-pyridazinyl)-4-piperidinylethyl-1-oxy)-4-t-butylidimethylsilyloxymethylthiazole (274mg, 54%), ¹H nmr; 0.11 (s, 6H), 0.94 (s, 9H), 1.3-1.87 (m, 7H), 2.58 (s, 3H), 2.93 (t, 2H), 4.31-4.35 (m, 2H), 4.48 (t, 2H), 4.64 (s, 2H), 6.51 (s, 1H), 6.93 (d, 1H), 7.11 (d, 1H).
- (d) A solution of tetrabutylammonium fluoride (1M in THF, 0.6ml, 0.6mmol) was added dropwise to a solution of 2-(1-(6-methyl-3-pyridazinyl)-4-piperidinylethyl-1-oxy)-4-t-butylidimethylsilyloxymethylthiazole (274mg, 0.6mmol) in THF (10ml) and the reaction was stirred under argon overnight. The mixture was partitioned between water (10ml) and ethyl acetate (40ml) then the organic layer was washed with brine, dried (MgSO₄) and concentrated. The residue was chromatographed on silica gel (25g; eluent 0%-10% isopropanol/ethyl acetate) to give 2-(1-(6-methyl-3-pyridazinyl)-4-piperidinylethoxy)-4-hydroxymethylthiazole (157mg, 0.47mmol) in 76% yield, ¹H nmr; 1.78-1.9 (m, 5H), 2.51 (s, 3H), 2.96 (t, 2H), 4.31-4.37 (m, 4H), 4.58 (s, 2H), 6.02 (s, 1H), 7.22 (d, 1H), 7.30 (d, 1H).
- (e) A solution of anhydrous DMSO (80μl, 1.13mmol) in DCM (1ml) was added to a solution of oxalyl chloride (45μl, 0.5mmol) in DCM (1ml) at -60°C. After 15min a solution of 2-(1-(3-methyl-6-pyridazinyl)-4-piperidinylethyl-1-oxy)-4-hydroxymethylthiazole (157mg, 0.5mmol) in DCM (2ml) was added. The reaction was stirred at -50°C for 10min then triethylamine (325μl, 2.33mmol) was added and the reaction allowed to warm to room temperature. The mixture was partitioned between DCM


- 42 -

(150ml) and dilute sodium bicarbonate solution (75ml) then washed with brine, dried (MgSO₄) and concentrated. The residue was adsorbed onto silica gel and chromatographed on silica gel (15g; eluent 65% ethyl acetate/hexane) to give 2-(1-(6-methyl-3-pyridazinyl)-4-piperidinyloxy)thiazole-4-carboxaldehyde (103mg, 66%), ¹H nmr; 1.3-1.9 (m, 7H), 2.63 (s, 3H), 2.94 (m, 2H), 4.34-4.38 (m, 2H), 4.59 (t, 2H), 7.04 (d, 1H), 7.20 (d, 1H), 7.61 (s, 1H), 9.74 (s, 1H).

(f) The O-ethyl oxime ether (Compound 155) of the aldehyde in part (e) was prepared from by reaction with ethoxyamine following similar conditions to those described in Example 1 and the spectra for Compound 155 are given in Table 11 below.

Example 8

Preparation of 4-{N-(6-Chloro-3-pyridazinyl)-N-methyl-5-aminopentan-1-oxy}benzaldehyde O-ethyloxime (Compound No. 161)



(a) A mixture of 5-amino-1-pentanol (433mg, 4.2mmol), dichloropyridazine (1.25g, 8.39mmol) and sodium carbonate (890mg, 8.39mmol) was stirred in 1,4-dioxane (40 ml) and heated at 70-80° for 3 days under an atmosphere of argon. The solvent was removed under reduced pressure and the residue was partitioned between dichloromethane (300 ml) and water (38 ml). The organic layer was separated, dried and concentrated to give an orange solid which was chromatographed on silica, using hexane/ethyl acetate (1:1). The product, 5-(6-chloro-3-pyridazinyl)amino-1-pentanol was isolated as a pale yellow solid (202 mg, 22%).

(b) 5-(6-Chloro-3-pyridazinyl)amino-1-pentanol was coupled to 4-hydroxybenzaldehyde using the Mitsunobu Reaction and following essentially the same method as described in Example 2, part (b). The product, 4-{N-(6-Chloro-3-pyridazinyl)-5-aminopentan-1-oxy}benzaldehyde, was isolated by chromatography and characterised by its nmr spectrum


- 43 -

in CDCl₃; 1.65 (m, 2H); 1.76 (m, 2H); 1.90 (m, 2H); 3.45 (t, 2H); 4.15 (t, 2H); 6.92 (d, 1H); 7.10 (d, 2H); 7.30 (d, 1H); 7.89 (d, 2H); 9.86 (s, 1H).

- (c) Sodium hydride (10mg, 0.24mmol) was added to a solution of 4-{N-(6-Chloro-3-pyridazinyl)-5-aminopentan-1-oxy}benzaldehyde (51mg, 0.16mmol) in THF (3.5 ml) and the mixture was stirred at room temperature for 30 minutes. Methyl iodide (50μl, 0.8mmol) was added to the reaction mixture and the suspension was stirred at room temperature for 48 hours. The reaction mixture was poured into water (1.5ml) and concentrated under reduced pressure. The residue was partitioned between water (2 ml) and ethyl acetate (40 ml), shaken thoroughly and the organic layer was separated, dried and evaporated to give a yellow solid. Purification by chromatography on silica gel (6g, 30% ethyl acetate/hexane) gave 4-{N-(6-Chloro-3-pyridazinyl)-N-methyl-5-aminopentan-1-oxy}benzaldehyde (16mg, 30%) as a pale yellow oil.
- (d) Reaction of 4-{N-(6-Chloro-3-pyridazinyl)-N-methyl-5-aminopentan-1-oxy}benzaldehyde with ethoxyamine following similar conditions to those in Example 1 gave 4-{N-(6-Chloro-3-pyridazinyl)-N-methyl-5-aminopentan-1-oxy}benzaldehyde O-ethyloxime (Compound 161) as a colourless oil. The nmr and mass spectral data are given below in Table 11.

Example 9

Preparation of 4-{2-[1-{5-Methyl-2-(1,3,4-thiadiazinyl)}-4-piperidinyl]ethoxy}benzaldehyde O-ethyloxime (Compound 158)



- (a) A suspension containing 2-bromo-5-methyl-1,3,4-thiadiazole (Modarai, B., *et al.* J. Heterocyclic Chem. (1974) **11**, 343-5) (100mg, 0.56mmol), 4-piperidine ethanol (87mg, 0.67mmol) and potassium carbonate (77mg, 0.56mmol) was heated overnight at 120°C. The reaction was cooled and the mixture partitioned between water (10ml) and ethyl

acetate (30ml), then the organic layer was washed with brine, dried (Na_2SO_4) and concentrated. Chromatography of the residue on silica gel (8g; eluent 2.5% methanol/DCM) gave 1-(5-methyl-1,3,4-thiadiazol-2-yl)-4-(2-hydroxyethyl)piperidine (41mg, 32%), ^1H nmr: 1.33 (m, 2H), 1.54 (q, 2H), 1.7 (m, 1H), 1.79 (m, 2H), 2.54 (s, 3H), 3.08 (m, 2H), 3.71 (t, 2H), 3.88 (m, 2H).

(b) 1-(5-methyl-2-[1,3,4-thiadiazolyl])-4-piperidineethanol from part (a) was converted into the oxime ether Compound No. 158 by reaction with 4-hydroxybenzaldehyde and ethoxyamine following a similar method to that described in Example 1. The spectral data are recorded below in Table 11.

Example 10

The Compound No's 84, 152-154, 157, 159-160, 196-207, 210 and 212 from Table 6 above were prepared using the appropriate heterocycle and essentially the same method as described in Example 9 for Compound 158. The compounds were purified by column chromatography on silica gel and characterised by their nuclear magnetic resonance (nmr) spectra and Mass Spectral (MS) data which are summarised in Table 11 below.

Example 11

Most of the compounds in Tables 1-8 were prepared from the appropriate heterocyclic alcohol derivative (Het-A-Alk-OH) by reaction with the appropriate hydroxyaromatic carbonyl compound ($\text{HO-Ar-C}(\text{X}^2)=\text{O}$) or hydroxy aromatic oxime ether ($\text{HO-Ar-C}(\text{X}^2)=\text{NO-X}^1$) following similar conditions to those described in Examples 1 and 2. An alternative method which was used for some compounds is the reaction of the heterocyclic alkyl halide (Het-A-Alk-Cl) with the appropriate hydroxyaromatic carbonyl compound ($\text{HO-Ar-C}(\text{X}^2)=\text{O}$) or hydroxy aromatic oxime ether ($\text{HO-Ar-C}(\text{X}^2)=\text{NO-X}^1$). The compounds were generally purified by column chromatography on silica gel and characterised by their nuclear magnetic resonance (nmr) spectra and Mass Spectral (MS) data. For convenience the nmr data are recorded in Table 11 below.

Table 11

Compd Number	MS data (ESI)	NMR data: Proton Chemical Shift, δ in ppm (CDCl ₃ unless otherwise noted)
26	-	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.0 (s, 3H); 4.05 (t, 2H); 4.17 (q, 2H); 4.27 (bd, 2H); 6.85-6.95 (2xd, 3H); 7.10 (d, 1H); 7.52 (d, 2H); 8.03 (s, 1H)
27	-	1.31 (t, 3H); 2.78 (m, 4H); 3.72 (m, 4H); 4.22 (m, 6H); 6.91 (m, 4H); 7.52 (d, 2H); 8.02 (s, 1H)
28	-	1.31 (t, 3H); 1.86 (m, 5H); 3.19 (m, 2H); 3.92 (m, 2H); 4.20 (m, 4H); 6.89 (m, 3H); 7.01 (d, 1H); 7.50 (d, 2H); 8.01 (s, 1H)
31	397 (M+Na)	1.32 (t, 3H); 1.35-1.51 (m, 2H); 1.95-2.17 (m, 3H); 3.01 (t, 2H); 3.86 (d, 2H); 4.22 (q, 2H); 4.38-4.45 (m, 2H); 6.91 (m, 3H); 7.17 (d, 1H); 7.48 (d, 2H); 8.02 (s, 1H)
32	425 (M+Na)	1.25-1.35 (m, 7H); 1.45-1.50 (m, 2H); 1.65-1.87 (m, 5H); 3.01 (m, 2H); 4.00 (bt, 2H); 4.21 (q, 2H); 4.37-4.40 (m, 2H); 6.89 (d, 3H); 7.21 (d, 1H); 7.53 (d, 2H); 8.04 (s, 1H)
33	405.1693 (M+1)	1.30 (m, 2H); 1.75-1.95 (m, 5H); 2.97 (t, 2H); 3.87 (s, 3H); 3.99 (s, 3H); 4.10 (t, 2H); 4.35 (d, 2H); 6.85 (d, 1H); 6.90 (d, 1H); 7.00 (dd, 1H); 7.15 (d, 1H); 7.25 (d, 1H); 8.00 (s, 1H)
36	434 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.98 (bt, 2H); 4.21 (t, 2H); 4.28 (q, 2H); 4.33 (bd, 2H); 6.87 (d, 1H); 7.06 (d, 1H); 7.16 (d, 1H); 7.73 (dd, 1H); 8.02 (s, 1H); 8.05 (d, 1H)
37	405 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.22 (q, 2H); 4.30 (bd, 2H); 6.40-6.55 (m, 3H); 6.93 (dd, 1H); 7.01 (d, 1H); 8.02 (s, 1H); 10.05 (bs, 1H)
40	417 (M+1)	1.20-1.40 (m, 2H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.0 (t, 2H); 4.25 (bd, 2H); 4.65 (m, 2H); 5.10 (d, 1H); 5.22 (d, 1H); 5.35 (bs, 1H); 5.98 (m, 1H); 6.30 (d, 1H); 6.55 (m, 2H); 6.79 (d, 1H); 7.02 (d, 1H); 7.95 (s, 1H)

41	389 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.38 (bd, 2H); 6.90 (bd, 2H); 7.05-7.30 (m, 4H); 8.02 (s, 1H)
42	403 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.15 (s, 3H); 2.95 (bt, 2H); 3.95 (t, 2H); 4.18 (q, 2H); 4.32 (bd, 2H); 6.77 (d, 1H); 6.86 (d, 1H); 7.13 (d, 1H); 7.29 (d, 1H); 7.41 (s, 1H); 8.01 (s, 1H)
43	415 (M+1)	1.30 (m, 2H); 1.65-1.95 (m, 5H); 2.20 (s, 3H); 2.95 (t, 2H); 4.08 (t, 2H); 4.35 (d, 2H); 4.65 (d, 2H); 5.17 (dd, 1H); 5.33 (dd, 1H); 6.05 (m, 1H); 6.75 (d, 1H); 6.87 (d, 1H); 7.13 (d, 1H); 7.27 (d, 1H); 7.41 (s, 1H); 8.07 (s, 1H)
44	389 (M+1)	1.30 (m, 2H); 1.65-1.90 (m, 5H); 2.18 (s, 3H); 2.95 (t, 2H); 3.88 (s, 3H); 3.95 (t, 2H); 4.29 (d, 2H); 6.75 (d, 1H); 6.85 (d, 1H); 7.08 (d, 1H); 7.28 (d, 1H); 7.34 (s, 1H); 7.90 (s, 1H)
45	417 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.28 (s, 6H); 2.95 (bt, 2H); 3.82 (t, 2H); 4.18 (q, 2H); 4.32 (bd, 2H); 6.87 (d, 1H); 7.13 (d, 1H); 7.24 (s, 2H); 7.98 (s, 1H)
46	369 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.53 (s, 3H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.21 (q, 2H); 4.35 (bd, 2H); 6.82-6.95 (m, 2H); 7.05-7.30 (m, 4H); 8.01 (s, 1H)
48	355 (M+1)	1.30 (m, 2H); 1.65-1.95 (m, 5H); 2.50 (s, 3H); 2.92 (t, 2H); 3.98 (s, 3H); 4.05 (t, 2H); 4.32 (d, 2H); 6.86-6.89 (m, 2H); 7.05 (d, 1H); 7.10 (d, 1H); 7.16 (d, 1H); 7.28 (dd, 1H); 8.02 (s, 1H)
49	355 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.91 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.38 (bd, 2H); 6.85-6.95 (m, 3H); 7.12 (dd, 1H); 7.49 (d, 2H); 8.01 (s, 1H); 8.50 (d, 1H)
50	419 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 3.78 (s, 3H); 3.95 (t, 2H); 4.18 (q, 2H); 4.32 (bd, 2H); 6.42 (dd, 1H); 6.48 (dd, 1H); 6.88 (d, 1H); 7.15 (d, 1H); 7.18 (dd, 1H); 8.35 (s, 1H)
51	383 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.25 (s, 3H); 2.57 (s, 3H); 2.95 (bt, 2H); 4.08 (t, 2H); 4.23 (q, 2H); 4.35 (bd, 2H); 6.83 (d, 2H); 6.87 (d, 1H); 7.09 (d, 1H); 7.33 (d, 1H); 7.44 (bs, 1H); 8.01

		(s, 1H)
52	369 (M+1)	1.20-1.45 (m, 2H); 1.70-1.90 (m, 5H); 2.20 (s, 3H); 2.53 (s, 3H); 2.90 (t, 2H); 3.90 (s, 3H); 4.08 (t, 2H); 4.31 (d, 2H); 6.75 (d, 1H); 6.85 (d, 1H); 7.04 (d, 1H); 7.30 (dd, 1H); 7.42 (d, 1H); 7.95 (s, 1H)
54	397 (M+1)	0.97 (t, 3H); 1.30 (m, 2H); 1.60-1.95 (m, 7H); 2.18 (s, 3H); 2.55 (s, 3H); 2.92 (t, 2H); 4.00-4.22 (m, 4H); 4.33 (d, 2H); 6.78 (d, 1H); 6.87 (d, 1H); 7.08 (d, 1H); 7.32 (dd, 1H); 7.45 (d, 1H); 8.02 (s, 1H)
55	-	1.31 (t, 3H); 1.8-2.2 (m, 4H); 3.55-3.7 (m, 2H); 3.80-3.98 (m, 2H); 4.22 (q, 2H); 4.61 (m, 1H); 6.85-6.98 (dd, 3H); 7.21 (d, 1H); 7.50 (d, 2H); 8.01 (s, 1H)
56	-	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.46 (bd, 2H); 6.89 (d, 2H); 6.92 (d, 1H); 7.4-7.6 (m, 5H); 7.65 (d, 1H); 7.96-8.05 (m, 3H)
57	389 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.22 (q, 2H); 4.33 (bd, 2H); 6.87 (bd, 3H); 7.16 (d, 1H); 7.21 (s, 1H); 7.88 (d, 2H)
58	423 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 3.05 (bt, 2H); 4.05 (t, 2H); 4.20 (q, 1.7H, trans); 4.26 (q, 0.3H, cis); 4.55 (m, 2H); 6.87 (d, 2H); 6.93 (d, 1H); 7.21 (d, 0.3H, cis); 7.44 (d, 1H); 7.51 (d, 1.70H, trans); 7.87 (s, 0.15H, cis); 8.02 (s, 0.85H, trans)
59	-	(d ⁶ -DMSO) 1.20-1.40 (m, 2H); 1.65-1.95 (m, 5H); 2.49 (s, 3H); 2.91 (bt, 2H); 4.15 (t, 2H); 4.37 (bd, 2H); 4.78 (q, 2H); 7.08 (d, 1H); 7.25 (d, 2H); 7.29 (d, 1H); 7.64 (d, 2H); 8.41 (s, 1H)
61	375 (M+1)	Not recorded
67	356 (M+1)	Not recorded
68	370 (M+1)	Not recorded
70	356 (M+1)	Not recorded
71	370 (M+1)	Not recorded
73	376 (M+1)	Not recorded

75	376 (M+1)	Not recorded
76	390 (M+1)	Not recorded
77	402 (M+1)	
84	422 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.89 (bt, 2H); 4.03 (t, 2H); 4.17 (q, 2H); 4.39 (bd, 2H); 6.65 (d, 1H); 6.87 (d, 2H); 7.45 (d, 2H); 7.58 (dd, 1H); 8.02 (s, 1H); 8.38 (bs, 1H)
85	383 (M+1)	0.97 (t, 3H); 1.32-1.34 (m, 1H); 1.69-1.88 (m, 8H); 2.52 (s, 3H); 2.88-2.95 (m, 2H); 4.02-4.10 (m, 2H); 4.31-4.34 (m, 4H); 6.84-6.88 (m, 3H); 7.03 (d, 1H); 7.49 (d, 2H); 8.02 (s, 1H)
86	399 (M+1)	1.25-1.34 (m, 1H); 1.74-1.90 (m, 6H); 2.65 (s, 3H); 3.05 (m, 2H); 3.41 (s, 3H); 3.69 (t, 2H); 4.05 (t, 2H); 4.29 (t, 2H); 4.32-4.40 (m, 2H); 6.87 (m, 3H); 7.10 (d, 1H); 7.52 (d, 2H); 8.08 (s, 1H)
88	379 (M+1)	1.29-1.38 (m, 2H); 1.73-1.86 (m, 6H); 2.52 (s, 3H); 2.88-2.94 (m, 2H); 4.06 (t, 2H); 4.31-4.34 (m, 2H); 4.74 (s, 2H); 6.85-6.91 (m, 3H); 7.06 (d, 1H); 7.51 (d, 2H); 8.06 (s, 1H)
89	389 (M+1)	Not recorded
91	389 (M+1)	Not recorded
92	403 (M+1)	Not recorded
94	369 (M+1)	Not recorded
95	383 (M+1)	Not recorded
97	369 (M+1)	Not recorded
98	383 (M+1)	Not recorded
106	369 (M+1)	Not recorded
108	311 (M+Na)	1.52 (t, 3H); 2.16 (m, 2H); 2.20 (s, 3H); 2.82 (t, 2H); 4.01 (t, 2H); 4.20 (q, 2H); 5.84 (s, 1H); 6.85 (d, 2H); 7.51 (d, 2H); 8.01 (s, 1H)
109	-	2.16-2.21 (m, 4H); 2.22 (s, 9H); 2.99 (t, 2H); 3.81 (t, 2H); 3.97 (s, 3H); 5.87 (s, 1H); 7.28 (s, 2H)
112	331 (M+1)	0.97 (t, 3H); 1.70-1.76 (m, 2H); 2.16-2.20 (m, 2H); 2.20-2.27 (m, 9H); 2.99 (t, 2H); 3.82 (t, 2H); 4.10 (t, 2H); 5.87 (s, 1H); 7.23 (s, 2H); 7.97 (s, 1H)

118	328 (M+1)	2.17-2.23 (m, 2H); 2.27 (s, 9H); 2.99 (t, 2H); 3.83 (t, 2H); 4.77 (s, 2H); 5.87 (s, 1H); 7.27 (s, 2H); 8.03 (s, 1H)
119	349 (M+Na)	2.17-2.20 (m, 2H); 2.27 (s, 9H); 2.48 (t, 1H); 2.99 (t, 2H); 3.82 (t, 2H); 4.75 (d, 2H); 5.87 (s, 1H); 7.26 (s, 2H); 8.02 (s, 1H)
120	381 (M+Na)	0.92-1.3 (m, 7H); 1.71-1.82 (m, 4H); 2.26 (s, 9H); 2.72 (t, 2H); 3.75 (t, 2H); 4.20 (q, 2H); 5.81 (s, 1H); 7.24 (s, 2H); 7.91 (s, 1H)
121	395 (M+Na)	1.26-1.33 (m, 5H); 1.39-1.43 (m, 4H); 1.67-1.81 (m, 4H); 2.25 (s, 3H); 2.26 (s, 6H); 2.70 (t, 2H); 3.75 (t, 2H); 4.20 (q, 2H); 5.79 (s, 1H); 7.23 (s, 2H); 7.97 (s, 1H)
122	367 (M+Na)	1.31 (t, 3H); 1.53-1.60 (m, 2H); 1.81 (m, 4H); 2.26 (s, 9H); 2.75 (t, 2H); 3.76 (t, 2H); 4.21 (q, 2H); 7.23 (s, 2H); 7.97 (s, 1H)
123	353 (M+Na)	1.29 (t, 3H); 1.86-1.95 (m, 4H); 2.27 (s, 9H); 2.82 (t, 2H); 3.78 (t, 2H); 4.19 (q, 2H); 5.85 (s, 1H); 7.23 (s, 2H); 7.98 (s, 1H)
124	393 (M+Na)	2.19 (m, 2H); 2.27 (s, 9H); 2.99 (t, 2H); 3.83 (t, 2H); 4.49 (q, 2H); 5.87 (s, 1H); 7.24 (s, 2H); 8.03 (s, 1H)
125	383 (M+Na)	1.24 (t, 3H); 2.17 (m, 2H); 2.26-2.27 (m, 9H); 2.98 (t, 2H); 3.56 (q, 2H); 3.71-3.73 (m, 2H); 3.80 (t, 2H); 4.29 (t, 2H); 5.86 (s, 1H); 7.19 (s, 2H); 8.02 (s, 1H)
126	367 (M+Na)	2.16-2.29 (m, 14H); 2.99 (t, 2H); 3.81 (t, 2H); 4.62 (s, 2H); 5.87 (s, 1H); 7.23 (s, 2H); 8.10 (s, 1H)
127	-	1.31 (t, 3H); 2.24-2.28 (m, 8H); 3.12 (t, 2H); 3.86 (t, 2H); 4.20 (q, 2H); 6.36 (s, 1H); 7.41-7.43 (m, 3H); 7.78-7.81 (m, 2H); 7.97 (s, 1H)
128	383 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 3.05 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.35 (bd, 2H); 6.88 (d, 2H); 6.90 (d, 1H); 7.52 (d, 2H); 7.72 (d, 1H); 8.02 (s, 1H); 10.11 (s, 1H)
129	385 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.95 (bt, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 4.35 (bd, 2H); 4.80 (s, 2H); 6.87 (d, 2H); 6.95 (d, 1H); 7.05 (d, 1H); 7.52 (d, 2H); 8.02 (s, 1H)
130	331 (M+1)	1.25-1.34 (m, 6H); 2.21 (m, 2H); 2.25 (s, 6H); 2.70 (q, 2H); 2.99 (t, 2H); 3.83 (t, 2H); 4.21 (q, 2H); 5.89 (s, 1H); 7.23 (s, 2H); 7.96

		(s, 1H)
131	345 (M+1)	0.96 (t, 3H); 1.31 (t, 3H); 1.72 (m, 2H); 2.18 (m, 2H); 2.27 (s, 6H); 2.64 (t, 2H); 2.99 (t, 2H); 3.81 (t, 2H); 4.20 (q, 2H); 5.88 (s, 1H); 7.23 (s, 2H); 7.96 (s, 1H)
132	317 (M+1)	1.24-1.33 (m, 6H); 2.22 (s, 6H); 2.69 (q, 2H); 3.22 (t, 2H); 4.06 (t, 2H); 4.20 (q, 2H); 6.04 (s, 1H); 7.26 (s, 2H); 7.96 (s, 1H)
134	335 (M+1)	2.20 (m, 2H); 2.27 (s, 6H); 2.99 (t, 2H); 3.82 (t, 2H); 4.31-4.34 (m, 1H); 4.41-4.43 (m, 1H); 4.59-4.62 (m, 1H); 4.75-4.78 (m, 1H); 5.87 (s, 1H); 7.23 (s, 2H); 8.03 (s, 1H)
135	384 (M+1)	Not recorded
136	384 (M+1)	Not recorded
138		1.22-1.33 (m, 6H); 1.86-1.97 (m, 4H); 2.27 (s, 6H); 2.67 (q, 2H); 2.81 (t, 2H); 3.79 (t, 2H); 4.20 (q, 2H); 5.78 (s, 1H); 7.24 (s, 2H); 7.97 (s, 1H)
139	359 (M+1)	0.98 (t, 3H); 1.32 (t, 3H); 1.65 (m, 2H); 1.85-1.98 (m, 4H); 2.27 (s, 6H); 2.62 (t, 2H); 2.82 (t, 2H); 3.79 (t, 2H); 4.22 (q, 2H); 5.85 (s, 1H); 7.24 (s, 2H); 7.98 (s, 1H)
145	385.2229 (M+1)	1.20-1.40 (m, 5H); 1.65-1.95 (m, 5H); 2.52 (s, 3H); 2.90 (t, 2H); 4.03 (t, 2H); 4.19 (q, 2H); 4.32 (d, 2H); 6.40-6.50 (m, 2H); 6.85 (d, 1H); 7.03 (d, 1H); 7.05 (d, 1H); 8.05 (s, 1H); 10.12 (s, 1H)
146	385.2246 (M+1)	1.20-1.40 (m, 5H); 1.70-1.90 (m, 5H); 2.53 (s, 3H); 2.91 (t, 2H); 4.12 (t, 2H); 4.20 (q, 2H); 4.30 (d, 2H); 5.75 (br s, 1H); 6.82 (d, 1H); 6.86 (d, 1H); 7.02 (dd, 1H); 7.06 (d, 1H); 7.28 (d, 1H); 7.96 (s, 1H)
147	363 (M+1)	(CD ₃ OD) 1.32 (t, 3H); 1.64 (m, 2H); 1.75 (m, 2H); 1.88 (m, 2H); 3.44 (t, 2H); 4.06 (t, 2H); 4.20 (q, 2H); 6.94 (m, 3H); 7.30 (d, 1H); 7.54 (m, 2H); 8.05 (s, 1H)
149	404 (M+1)	Not recorded
150	403 (M+1)	Not recorded
152	Not recorded	1.31 (t, 3H); 2.81-2.97 (m, 6H); 3.68 (m, 4H); 4.21 (q, 2H); 4.21-4.26 (m, 2H); 6.90 (d, 2H); 7.51 (d, 2H); 7.86 (s, 1H); 8.02 (s,

		1H); 8.07 (s, 1H)
153	415 (M+1)	1.38-1.45 (m, 2H); 1.88-1.92 (m, 3H); 1.79 (t, 2H); 3.17-3.27 (m, 2H); 3.93 (s, 3H); 3.97-4.05 (m, 2H); 4.05 (t, 2H); 6.86 (d, 2H); 7.51 (d, 2H); 7.99 (s, 1H). F19 -60.05ppm
154	429 (M+1)	1.31 (t, 3H); 1.4-1.5 (m, 2H); 1.78 (t, 2H); 1.89-1.93 (m, 3H); 3.19-3.27 (m, 2H); 3.99-4.05 (m, 2H); 4.07 (t, 2H); 4.21 (q, 2H); 6.87 (d, 2H); 7.52 (d, 2H); 8.01 (s, 1H)
155	376 (M+1)	1.24-1.37 (m, 5H); 1.73-1.85 (m, 5H); 2.52 (s, 3H); 2.89 (t, 2H); 4.20 (q, 2H); 4.33-4.40 (m, 2H); 4.52 (t, 2H); 6.87-6.90 (m, 2H); 7.05 (d, 1H); 7.95 (s, 1H)
156	362 (M+1)	1.23-1.37 (m, 2H); 1.73-1.85 (m, 5H); 2.52 (s, 3H); 2.88 (t, 2H); 3.95 (s, 3H); 4.28-4.33 (m, 2H); 4.52 (t, 2H); 6.87-6.89 (m, 2H); 7.05 (d, 1H); 7.93 (s, 1H)
157	361 (M+1)	1.39-1.43 (m, 2H); 1.77-2.04 (m, 5H); 2.57 (s, 3H); 3.12 (t, 2H); 3.92-3.95 (m, 2H); 3.95 (s, 3H); 4.04 (t, 2H); 6.88 (d, 2H); 7.50 (d, 2H); 8.01 (s, 1H)
158	375 (M+1)	1.31 (t, 3H); 1.39-1.43 (m, 2H); 1.76-2.03 (m, 5H); 2.56 (s, 3H); 3.11 (t, 2H); 3.91-3.94 (m, 2H); 4.04 (t, 2H); 4.20 (q, 2H); 6.88 (d, 2H); 7.52 (d, 2H); 8.02 (s, 1H)
159	Not recorded	1.25-1.33 (m, 2H); 1.75-1.88 (m, 5H); 2.88-2.94 (m, 2H); 3.95 (s, 3H); 4.05 (t, 2H); 4.23-4.27 (m, 2H); 6.89 (d, 2H); 7.49 (d, 2H); 7.86 (s, 1H); 8.01 (s, 1H); 8.04 (s, 1H)
160	Not recorded	1.29-1.36 (m, 5H); 1.74-1.88 (m, 5H); 2.88-2.95 (m, 2H); 4.05 (t, 2H); 4.17-4.24 (m, 4H); 6.88 (d, 2H); 7.52 (d, 2H); 7.86 (s, 1H); 8.02 (s, 1H); 8.04 (s, 1H)
161	377 (M+1)	(CD ₃ OD) 1.32 (t, 3H); 1.57 (m, 2H); 1.74 (m, 2H); 1.87 (m, 2H); 3.15 (s, 3H); 3.65 (t, 2H); 4.05 (t, 2H); 4.18 (q, 2H); 6.94 (m, 2H); 7.15 (d, 1H); 7.38 (d, 1H); 7.54 (m, 2H); 8.05 (s, 1H)
162	377 (M+1)	1.32 (t, 3H); 1.51 (m, 4H); 1.72 (m, 2H); 1.81 (m, 2H); 3.40 (m, 2H); 3.98 (t, 2H); 4.20 (q, 2H); 5.94 (bs, 1H); 6.80 (bd, 1H); 6.88 (m, 2H); 7.22 (m, 1H); 7.50 (m, 2H); 8.02 (s, 1H)

163	349 (M+1)	1.32 (t, 3H); 1.90 (m, 4H); 3.50 (m, 2H); 4.04 (m, 2H); 4.20 (q, 2H); 5.93 (bs, 1H); 6.80 (m, 1H); 6.88 (m, 2H); 7.22 (d, 1H); 7.51 (m, 2H); 8.02 (s, 1H)
167	423 (M+1)	Not recorded
168	437 (M+1)	Not recorded
171	369 (M+1)	Not recorded
172	383 (M+1)	Not recorded
177	375 (M+1)	Not recorded
180	409 (M+1)	Not recorded
182	395 (M+1)	Not recorded
183	409 (M+1)	Not recorded
185	397.2584 (M+1)	1.25-1.45 (m, 5H); 1.70-1.90 (m, 5H); 2.35 (s, 6H); 2.50 (s, 3H); 2.90 (t, 2H); 4.02 (t, 2H); 4.19 (q, 2H); 4.30 (d, 2H); 6.60 (s, 2H); 6.85 (d, 1H); 7.03 (d, 1H); 8.36 (s, 1H)
186	383.2448 (M+1)	1.30 (m, 2H); 1.70-1.90 (m, 5H); 2.40 (s, 6H); 2.52 (s, 3H); 2.90 (t, 2H); 3.94 (s, 1H); 4.02 (t, 2H); 4.32 (d, 2H); 6.60 (s, 2H); 6.88 (d, 1H); 7.02 (d, 1H); 8.32 (s, 1H)
187	399.4 (M+1)	1.20-1.40 (m, 5H); 1.70-1.95 (m, 5H); 2.52 (s, 3H); 2.92 (t, 2H); 3.85 (s, 3H); 4.03 (t, 2H); 4.15 (q, 2H); 4.31 (d, 2H); 6.42 (d, 1H); 6.47 (dd, 1H); 6.86 (d, 1H); 7.05 (d, 1H); 7.71 (d, 1H); 8.39 (s, 1H)
188	383.2435 (M+1)	1.20-1.45 (m, 5H); 1.70-1.90 (m, 5H); 2.38 (s, 3H); 2.51 (s, 3H); 2.90 (t, 2H); 4.05 (t, 2H); 4.22 (q, 2H); 4.32 (d, 2H); 6.69 (d, 1H); 6.72 (dd, 1H); 6.83 (d, 1H); 7.06 (d, 1H); 7.65 (dd, 1H); 8.28 (s, 1H)
189	369.2272 (M+1)	1.30 (m, 2H); 1.70-1.90 (m, 5H); 2.38 (s, 3H); 2.51 (s, 3H); 2.90 (t, 2H); 3.98 (s, 3H); 4.05 (t, 2H); 4.31 (d, 2H); 6.71 (d, 1H); 6.72 (dd, 1H); 6.82 (d, 1H); 7.05 (d, 1H); 7.63 (dd, 1H); 8.26 (s, 1H)
190	397.2602 (M+1)	1.20-1.45 (m, 5H); 1.70-1.90 (m, 5H); 2.16 (s, 3H); 2.32 (s, 3H); 2.52 (s, 3H); 2.90 (t, 2H); 4.09 (t, 2H); 4.21 (q, 2H); 4.32 (d, 2H); 6.59 (s, 1H); 6.85 (d, 1H); 7.03 (d, 1H); 7.51 (s, 1H); 8.23 (s, 1H)

191	383.2436 (M+1)	1.32 (m, 2H); 1.72-1.90 (m, 5H); 2.18 (s, 3H); 2.38 (s, 3H); 2.54 (s, 3H); 2.89 (t, 2H); 3.98 (s, 3H); 4.05 (t, 2H); 4.32 (d, 2H); 6.59 (s, 1H); 6.87 (d, 1H); 7.05 (d, 1H); 7.52 (s, 1H); 8.28 (s, 1H)
192	397.2583 (M+1)	1.20-1.45 (m, 5H); 1.70-1.90 (m, 5H); 2.15 (s, 3H); 2.30 (s, 3H); 2.53 (s, 3H); 2.92 (t, 2H); 4.06 (t, 2H); 4.22 (q, 2H); 4.32 (d, 2H); 6.78 (d, 1H); 6.84 (d, 1H); 7.08 (d, 1H); 7.52 (d, 1H); 8.38 (s, 1H)
193	383.4 (M+1)	1.30 (m, 2H); 1.72-1.90 (m, 5H); 2.15 (s, 3H); 2.30 (s, 3H); 2.52 (s, 3H); 2.90 (t, 2H); 3.95 (s, 3H); 4.03 (t, 2H); 4.33 (d, 2H); 6.71 (d, 1H); 6.85 (d, 1H); 7.04 (d, 1H); 7.53 (d, 1H); 8.35 (s, 1H)
194	377 (M+1)	1.42-1.85 (m, 8H); 3.14 (s, 3H); 3.63 (t, 2H); 3.93 (s, 3H); 4.02 (m, 3H); 6.94 (m, 2H); 7.14 (d, 1H); 7.38 (d, 1H); 7.54 (m, 2H); 8.05 (s, 1H)
195	363 (M+1)	(CD ₃ OD) 1.32 (t, 3H); 1.85 (m, 4H); 3.16 (s, 3H); 3.70 (m, 2H); 4.09 (m, 2H); 4.18 (q, 2H); 6.95 (m, 2H); 7.16 (d, 1H); 7.39 (d, 1H); 7.54 (m, 2H); 8.05 (s, 1H)
196	368.2343 (M+1)	1.20-1.40 (m, 5H); 1.70-1.90 (m, 5H); 2.39 (s, 3H); 2.80 (t, 2H); 4.05 (t, 2H); 4.21 (q, 2H); 4.32 (d, 2H); 6.45 (d, 2H); 6.88 (d, 2H); 7.35 (d, 1H); 7.51 (d, 1H); 8.03 (s, 1H)
197	418 (M+1)	1.30-1.34 (m, 5H); 1.70-1.95 (m, 5H); 3.0-3.15 (m, 2H); 3.94 (s, 3H); 4.05 (m, 4H); 4.33 (q, 2H); 6.87 (s, 2H); 7.41 (s, 1H); 7.50 (d, 2H); 8.01 (s, 1H)
198	432 (M+1)	1.29-1.39 (m, 8H); 1.76-1.88 (m, 5H); 3.00-3.09 (m, 2H); 4.06-4.07 (m, 4H); 4.20 (q, 2H); 4.33 (q, 2H); 6.87 (d, 2H); 7.41 (s, 1H); 7.50 (d, 2H); 8.02 (s, 1H)
199	375 (M+1)	Not recorded
200	380 (M+1)	Not recorded
202	402 (M+1)	Not recorded
204	369 (M+1)	Not recorded
206	396 (M+1)	Not recorded
207	410 (M+1)	Not recorded

- 54 -

208	Not recorded	1.31 (t, 3H); 1.2-1.5 (m, 2H); 1.7-2.0 (m, 5H); 3.05 (t, 2H); 3.9-4.1 (m, 5H); 4.20 (q, 2H); 4.55 (bd, 2H); 6.87 (d, 2H); 7.03 (d, 1H); 7.52 (d, 2H); 7.82 (d, 1H); 8.02 (s, 1H); 8.32 (s, 1H)
209	364 (M+1)	1.31 (t, 3H); 1.5-1.85 (m, 6H); 3.98 (t, 2H); 4.19 (q, 2H); 6.88 (m, 3H); 7.16 (d, 1H); 7.50 (d, 2H); 8.02 (s, 1H)
210	Not recorded	1.2-1.45 (m, 5H); 1.7-1.95 (m, 5H); 3.02 (t, 2H); 4.03 (t, 2H); 4.16 (q, 2H); 4.55 (bd, 2H); 6.89 (d, 2H); 7.45-7.65 (m, 4H); 7.80 (d, 1H); 8.02 (s, 1H); 8.58 (s, 1H)
211	Not recorded	1.30 (t, 3H); 4.24 (q, 2H); 7.30 (d, 2H); 7.55-7.75 (m, 4H); 8.09 (d, 1H); 8.14 (s, 1H); 8.58 (s, 1H)
212	Not recorded	1.25-1.40 (m, 5H); 1.70-1.95 (m, 5H); 2.30 (s, 3H); 2.45 (t, 2H); 4.08 (t, 2H); 4.20 (q, 2H); 4.36 (bd, 2H); 6.80 (s, 1H); 6.88 (d, 2H); 7.51 (d, 2H); 8.06 (s, 1H)
213	Not recorded	1.25-1.45 (m, 5H); 1.75-1.95 (m, 5H); 2.65 (s, 3H); 2.75-3.05 (m, 6H); 4.07 (t, 2H); 4.20 (q, 2H); 4.36 (d, 2H); 6.78 (d, 1H); 7.07 (d, 1H); 7.17-7.25 (m, 2H); 7.29 (d, 1H)

Example 12

Preparation of 4-{2-[1-(6-Formyl-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde

5 O-ethyloxime (Compound 128)

A solution of 4-{2-[1-(6-Methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde O-ethyloxime (200mg, 0.54mmol, Compound 2) and selenium dioxide (70mg, 0.63mmol) in 1,4-dioxane (5 ml) was stirred and heated at 70-80° for 60 hr. The reaction mixture was filtered to remove most of the black selenium powder and then the filtrate was concentrated and applied to a column of silica gel (20g). Elution with chloroform gave the aldehyde product (55mg, 26%, Compound 128) as the fastest running component (see Table 11 for the nmr and mass spectral data).

Compounds No. 129 and 208 were prepared from Compound No. 128 by standard reactions with sodium borohydride and methoxyamine.

Example 13

Anti-HRV activity in mammalian cell culture assays

Inhibition of viral cytopathic effect (CPE) and measurement of cytotoxicity

The ability of compounds to suppress virus replication and thereby protect cells from

- 5 HRV-induced CPE was measured using human embryo lung (MRC-5) and human epidermoid carcinoma of the mouth (KB) cells infected with HRV type 1A and HRV type 2, respectively. Cells grown in 96 well tissue culture plates using conventional mammalian tissue culture medium (such as minimum essential medium) supplemented with fetal calf serum were used in an assay essentially similar to that described by Sidwell and Huffman (Applied Microbiology, 22, 797-801 (1971)). Test compounds were dissolved in 100% anhydrous dimethyl sulfoxide and serially diluted in tissue culture medium. The antiviral potency of the test compounds was assessed by exposing replicate tissue culture wells to a selected dilution series of between 6 and 7 compound concentrations in the presence of sufficient test virus to invoke significant CPE over the
- 15 course of the assay. Control cells were also exposed to identical concentrations of compounds in the absence of virus or were infected with virus under the same conditions but in the absence of compounds. Compounds of established anti-HRV efficacy (enviroxime, ribavirin and pirodavir) were assayed by identical procedures in parallel to the test compounds. Tissue culture media were identically supplemented to maintain cell viability and support viral growth while suppressing bacterial growth over the period of the assay (supplements: 2% fetal calf serum, 0.01% sodium bicarbonate, 50 µg/ml gentamicin, 5 µM magnesium chloride, 10 mM of zinc chloride). The assays were incubated at 37°C in a 5% CO₂ atmosphere until significant CPE was observed by microscopic examination of the untreated, HRV infected control cells (generally between 5
- 25 and 8 days). At this time all infected cultures were examined by eye using a light microscope and CPE scored on a scale of 0 (no CPE) to 4 (maximum CPE). Uninfected treated cultures were similarly scored for cytotoxic effects (eg. cell enlargement, granularity, rounding, detachment). These scores were used to generate EC₅₀ (concentration of compound yielding 50% antiviral efficacy) and CC₅₀ (concentration of compound yielding 50% cytotoxicity) values by line regression analysis from plots of compound concentration versus % CPE or % cytotoxicity, respectively. As an alternative
- 30

to a CC_{50} value, cytotoxicity in some cases was expressed as the Minimum Toxic Concentration (MTC). The MTC corresponds to the lowest compound concentration at which cytotoxic effects were observed.

- In some cases the visual scoring system described above was validated by vital dye staining to measure cell viability. The vital dye technique used was a modification of the method described by McManus (Appl. Environment. Microbiol., 31, 35-38, 1976). After the assay had been scored by eye with the aid of a microscope, 100 μ l of neutral red (NR) solution (0.34% NR in phosphate buffered saline (PBS)) was added to each well and mixed gently. The assays were returned to the 37°C incubator for 2 hours to facilitate uptake of the NR by viable cells. The medium/NR mixture was then aspirated from the surface of the cells, which were washed twice with PBS. 0.25 ml of absolute ethanol containing Sorensen's citrate buffer I, was added with gentle mixing and the assays incubated at room temperature in the dark for 30 minutes to dissolve the NR. NR staining of viable cells was then quantified spectrophotometrically by measuring the colour density of the NR solution using a BioTek EL-309 microplate reader at dual wavelengths of 540 and 405 nm. The differences in the two readings were automatically determined to eliminate background errors. EC_{50} and CC_{50} values were determined by regression analysis matching compound concentration to NR staining.
- The results are shown in the Table 12 below. Selectivity indices (SI) are the CC_{50} or MTC divided by the EC_{50} .

Table 12

Compound No.	Activity on Rhinovirus Type 2 ^a			Activity on Rhinovirus Type 1A		
	EC ₅₀ (µg/ml)	CC ₅₀	SI	EC ₅₀ (µg/ml)	MTC	SI
1	< 0.001	> 1	> 1000	0.0002	> 10.0	>37317
1				0.003	>1	>312
2	0.0002	10	50,000	<0.000156	>50	> 320000
3	0.01	> 1	> 100	0.005	> 10.0	1841
4	0.5	> 1	> 2	0.39	10.00	25.55
5	0.009	>1	>111	<0.0032	>1	>312
6	0.1	> 50	> 500	0.06	> 10.00	> 167.09
7	0.15	>1	>7	<0.0032	>1	>312
8	0.03	>1	>33	<0.0032	>1	>312
9	0.08	>1	>13	<0.0032	>1	>312
10	0.4	>1	>3	0.0142	>1	>70.54
11	0.004	>1	>250	<0.0032	>1	>312
12	0.02	1	50	0.00355	>1	>273.7
13	0.006	0.5	83	<0.0032	>1	>312
14	0.046	0.6	13	<0.0032	>1	>312
15	0.9	0.6	<1	>1.0	>1.0	NA
16	<0.001	1	>1000	<0.0032	>1	>312
17	>1	>1	NA	0.00612	>1	>163.2
18	0.09	>1	>11	0.0063	>1	>158.6
19	0.019	>1	>53	<0.0032	>1	>312
20	3	2	1	3.28	> 50.00	> 15.24
21	0.3	>1	>3	>1	>1	NA
22	<0.05	20	>400	<0.16	36.0	>320
23	<0.05	17	>340	<0.16	>50	>320
24	<0.05	25	>500	<0.16	>50	>320
25	0.5	17	34	0.36	>50	>139.4

26	0.16	>1	>6	0.077	>1	>13.0
27	0.1	>1	>10	0.017	>1	>59.6
28	0.06	>1	>17	0.180	>1	>5.5
30				0.036	>1	>28
31	0.003	>1	>333	0.017	>1	>59.6
32	0.014	>1	>70	0.222	>1	>4.5
33	0.04	>1	>25	0.014	>1	>72.4
34	0.7	>1	>1	0.627	>1	>1.59
36	0.03	>1	>33	0.009	0.89	99.4
37	0.048	>1	>21	0.010	>1	>96.0
38				0.69	>1	>1.45
40	0.4	>1	>3	0.583	>1	>1.72
41	<0.001	>1	>1000	0.016	>1	>63.5
42	0.006	>1	>167	0.006	>1	>177.8
43	0.01	>1	>100	0.006	>1	>170
44	0.026	>1	>38	<0.003	>1	>312
45	0.03	>1	>32	0.029	>1	>34.0
46	NT			0.062	>1	>16.0
47	NT			0.066	>1	>15
48	NT			0.016	>1	>62
49	NT			0.056	>1	>17.8
50	NT			0.008	>1	>121.7
51	NT			<0.003	0.663	>207.3
52	NT			<0.003	>1	>312
53	NT			<0.003	0.667	>208
54	NT			0.007	0.663	91
55	NT			2.68	>10	>3
56	NT			2.31	>10	>3
57	0.00025	>0.1	>400	0.001	>0.1	>56.3
58	NT			0.498	>1	>2

59	NT			0.162	0.56	3.4
60	NT			0.183	>1	>17
61	NT			0.058	>1	>14
62	NT			0.067	>1	>14
63	NT			0.06	>1	>15
64	NT			0.05	>1	>17
65	NT			0.21	>1	>4.5
66	NT			0.05	>1	>18
67	NT			0.04	>1	>20
68	NT			0.04	>1	>25
69	NT			0.18	>1	>5
70	NT			0.05	>1	>16
71	NT			0.05	>1	>18
72	NT			0.16	>1	>6
73	NT			0.003	>1	>312
74	NT			0.02	>1	>46
75	NT			0.01	>1	>98
76	NT			0.01	>1	>98
77	NT			0.003	>1	>279
84	NT			0.05	>1	>19.6
85	NT			0.08	>1	>12
87	NT			0.01	>1	>51
88	NT			0.005	>1	>172
89	NT			0.005	>1	>174
91	NT			0.02	>1	>46
92	NT			0.20	>1	>5
94	NT			0.024	>1	>41
95	NT			0.30	>1	>3
98	NT			0.255	>1	>3
99	NT			0.205	>1	>4

WO 00/78746

PCT/AU00/00680

- 60 -

102	NT			0.059	>1	>17
103	NT			0.266	>1	>3
105	NT			0.126	>1	>8
107	NT			0.062	>1	>16
108	0.6	>1	>1	>1	>1	NA
109	NT			0.053	>1	>18.8
119	NT			0.046	>1	>21.4
120	NT			0.04	>1	>20
121	NT			0.05	>1	>16
122	NT			0.181	>1	>5
123	NT			0.060	>1	>16
124	NT			0.719	>1	>1
125	NT					
126	NT			NT		
127	NT			0.329	>1	>3
128	NT			0.063	>1	>15
129	NT			0.048	>1	>20
136	NT			0.598	>1	>1
137	NT			0.054	>1	>18
138	NT			0.07	>1	>15
139	NT			0.19	>1	>5
140	NT			0.016	>1	>61
141	NT			0.166	>1	>6
142	NT			0.055	>1	>18
143	NT			0.020	>1	>50
144	NT			<0.0032	>1	>312
145	NT			<0.0032	>1	>312
146	NT			0.051	>1	>19
147	NT			0.194	>1	>5
210	NT			3.96	>10	>2.5

211	NT			0.07	>10	>151
Comparative compound:						
Compound No. 110 of US Patent 4,992,433 ^a	2	30	15	12.06	> 50.00	> 4.14
Controls:						
Pirodavir	0.003	> 1	> 300	0.02	> 10.00	555.74
Ribavirin	NT			1.93	98.3	51.03
Enviroxime	NT			0.006	0.49	75.91

^aThe comparative compound is the aldehyde intermediate IIa in Example 1 of this invention.

Example 14

5 Activity against Enteroviruses in Mammalian cell culture assays

Compounds No 1 and 2 of the invention were tested against other picornaviruses using similar cell based assays to those described in Example 5 above and results are shown in Table 13 below.

10

Table 13

Compound Number	Activity on Enterovirus 70			Activity on Coxsackie A21		
	EC ₅₀ (μ g/ml)	CC ₅₀	SI	EC ₅₀ (μ g/ml)	CC ₅₀	SI
1	0.03	> 50	> 158 2	< 0.000156	> 50	> 320000
2	0.00698	4.48	6409	< 0.000156	3.43	> 21927
Controls:						
Ribavirin	> 100	> 100	-	> 100	> 100	-
Enviroxime	0.21	4.11	19.35	0.39	9.55	24.25

Example 15

Following a similar method to that described in Example 13 above, the anti-HRV-14 activity in mammalian cell culture assay was determined for the compounds of the

5 invention listed in Table 14 below.

10

Table 14

Compound No.	Activity on Rhinovirus Type 14		
	EC ₅₀ (µg/ml)	CC ₅₀	SI
2	0.0018/0.0009	>0.1	>55
5	0.0077	>0.1	>13
7	0.0068	>0.1	>14
8	0.0072	>0.1	>13
11	0.0077	>0.1	>13
13	0.0078	>0.1	>12
33	0.0138	>0.1	>7
42	0.0111	>0.1	>9
44	0.0194	>0.1	>5
51	0.0093	>0.1	>10
52	0.0054	>0.1	>18
145	0.0072	>0.1	>13
146	0.0084	>0.1	>11
154	0.0514	>0.5	>9
155	0.0138	>0.5	>36
158	0.00095	>0.5	>526
160	0.0502	>0.5	>9

161	0.0348	>0.5	>14
185	0.0697	>1	>14
186	0.0349	>1	>28
187	0.0103	>1	>97
188	0.0032	>1	>311
189	0.0011	>1	>872
190	0.0593	>1	>16
191	0.0256	>1	>39
192	0.0258	>1	>38
193	0.0308	>1	>32
195	0.038	>0.5	>13
196	0.0424	>1	>23
198	0.125	>0.5	>4
199	0.0402	>0.1	>2.5
200	0.021	>0.1	>4.8
201	0.0261	>0.1	>3.8
202	0.0593	>0.1	>1.7
203	0.060	>0.1	>1.7
204	0.0554	>0.1	>1.8
205	0.0638	>0.1	>1.6
206	0.0233	>0.1	>4.3
209	0.0157	>0.5	>31
212	0.0107	>0.5	>46
Comparative compound: Pleconaril	0.0608	>0.1	>1.6

Example 16

The Inhibitory Concentrations of several compounds of the present invention against Human Rhinovirus strains 1B, 3, 4, 5, 6, 8, 9, 11, 12, 13, 16, 17, 21, 25, 30, 32, 33, 38, 39, 40, 42, 43, 45, 48, 52, 54, 56, 57, 59, 60, 63, 67, 68, 69, 72, 73, 85, 86, 89, 91, 92 and 100 were determined by a standard CPE reduction assay similar to that described in Example 13. From these assays it was found that compounds 1 and 2 of the invention showed superior activity to Pirodavis on nearly all HRV strains tested and compound 24 of the invention showed superior activity to Pleconaril.

Example 17

The Inhibitory Concentrations of several compounds of the present invention against the Enterovirus strains Poliovirus 2, Echoviruses 2, 3, 9, 21 and 30 and Coxsackie B3 were determined by a standard CPE reduction assay similar to that described in Example 13. From these assays it was found that compounds 1 and 2 of the invention showed superior activity to Pirodavis on all strains tested.

Example 18

Comparison of Compound 2 of the invention with Pirodavis in a time of addition study using HRV-2

20

The CPE inhibition assay used in this study was performed as described by Sidwell and Huffman (Appl. Microbiol., 22, 7979, 1971) with slight modifications. For most time of addition experiments virus at a multiplicity of infection (MOI) = 0.001 was added to the monolayers (1×10^5 cells/well) in each plate and incubated at 37°C. At the appropriate time after virus exposure (0, 1, 2, 4, 6, 8, 24 hr post-virus exposure) Compound 2 or Pirodavis was added to the cells at varying concentrations without removal of the virus and without significantly altering the volume in the wells. The plates were incubated for 5 days at 37°C.

30 When a pre-treatment was done (-1 hr) compound was added to the wells and incubated for 1 hr at 37°C. Following the 1 hr incubation of the compound, virus was added to each well

in a volume that did not significantly alter the concentration of the drug and the plate was incubated for 5 days. For all other treatment times the two compounds were also added within 5 minutes of virus exposure (0 time) and incubated for 5 days.

- 5 The assay was stopped at the end of the fifth day when the virus CPE in the virus infected, untreated, control cells was seen in all cells. Both compounds were assayed for virus inhibition in quadruplicate cups in a 96-well microplate; duplicate wells were used for cytotoxicity controls at each compound dosage. For each compound, two wells were set aside as uninfected, untreated cell controls per test and four wells per test received virus
- 10 only and represented controls for virus replication. Changes due to CPE were graded on a scale of 1-4, grade 4 representing a scenario in which the entire (100%) monolayer in a well showed viral CPE. For all CPE-based assays the 50% effective concentration (EC_{50}) was calculated by regression analysis using the means of the CPE ratings at each concentration of compound.
- 15 Results: Neither compound was cytotoxic at the doses used in the study (up to 0.1 $\mu\text{g/ml}$). The EC_{50} values for the two compounds at the various time points are shown in the Table below.

Table 19 Effects of the time of addition of Compound 2 and Pirodavis to infected KB cells on the inhibition of HRV-2 replication

Time of addition of Compound (hr)	EC_{50} ($\mu\text{g/ml}$) for Compound 2 (visual assay)	EC_{50} ($\mu\text{g/ml}$) for Pirodavis (visual assay)
-1	0.002	0.023
0	0.002	0.004
1	0.008	0.1
2	0.02	>0.1
4	0.02	>0.1
6	0.02	>0.1
8	0.02	>0.1
24	0.1	>0.1

- The results confirm that Compound 2 is more active than Pirodavir when added at the same time as virus (0 hr). More significantly the results show that Compound 2 has a much stronger effect than Pirodavir when added prior to virus (-1 hr) and that Compound 2
- 5 has much more activity than Pirodavir when added several hours after cells have been exposed to virus. The data indicate that Compound 2 may have a different mode of action to Pirodavir and the data is also consistent with Compound 2 being more stable and therefore having a longer lasting activity against HRV.
- 10 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
- 15 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or
- 20 more of said steps or features.

- 67 -

CLAIMS:




1. A compound of formula I




its salts, and pharmaceutically acceptable derivatives thereof where

10 Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical;

A is O, S, NH, N(C₁₋₆ alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



- 68 -



where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6} alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C_{2-4} alkylene radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino;

Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino and R^8 is hydrogen or C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl; and

R^5 is hydrogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

Alk is C_{1-7} alkylene or a direct bond;

W is O, S, OCH_2 , a direct bond or NR^9 where R^9 is hydrogen or C_{1-6} alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;

- 69 -



X^1 is C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} haloalkenyl, C_{3-6} alkynyl, C_{3-6} haloalkynyl or C_{1-6} alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4} alkoxy, C_{2-6} alkoxyalkoxy, acyl or C_{1-4} alkylthio; and

- 5 X^2 is hydrogen, cyano, F, Cl, C_{1-4} alkyl, C_{1-4} haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;




with the proviso that when Alk is a direct bond and A is O, S, CH_2O or a direct bond, then

- 10 W is not O, S, OCH_2 or a direct bond.


2. A compound according to claim 1 wherein Het is a radical selected from:



- 70 -



- 71 -



(a-14)


5 wherein R¹ is hydrogen, C₁₋₆alkyl, halo, hydroxy, mercapto, haloC₁₋₄alkyl, amino, mono or di(C₁₋₆alkyl)amino, cyano, formyl, C₁₋₆alkoxy, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₆ haloalkoxy, aryloxy, C₁₋₆alkylthio, arylthio, C₁₋₆alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphinyl, arylsulphonyl, -CH=NO-C₁₋₄alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylcarbonyl or aryl;

10 R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo or, in radicals (a-1), (a-4), (a-7) and (a-13), R¹ and R², or R² and R³ combined may represent a bivalent radical of formula -CH=CH-CH=CH- or (CH₂)_p where p is an integer from 2 to 4;

15 Y is O or S; and

Y' is O, S, SO or SO₂.

3. A compound according to claim 1 wherein Ar is a radical selected from
20




(c-1)



(c-2)


- 72 -



(c-3)



(c-4)



(c-5)



(c-6)

where Y is as defined above; and

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₆alkyl, hydroxy C₁₋₆alkyl, halo, amino, cyano, nitro, C₁₋₆alkoxy, hydroxy, C₁₋₆alkylthio, or trifluoromethyl.

4. A compound according to claim 2 wherein Het is a radical of formula (a-1), (a-2) or (a-8).


5. A compound according to claim 2 wherein R¹ is selected from hydrogen, methyl, ethyl, chloro, methoxy and trifluoromethyl.

6. A compound according to claim 2 wherein R² and R³ are independently hydrogen, chloro or methyl.

7. A compound according to claim 2 wherein Y is O or S.

8. A compound according to claim 1 wherein A is O, NH, NMe, a bond or a radical of formula (b-1).
9. A compound according to claim 1 wherein Z is CH or N.
10. A compound according to claim 1 wherein Alk is C₁₋₆alkylene or a direct bond.
11. A compound according to claim 1 wherein W is O.
12. A compound according to claim 3 wherein Ar is a radical of formula (c-1), (c-2) or (c-4).
13. A compound according to claim 3 wherein R¹⁰ and R¹¹ are each independently H, methyl, chloro, hydroxy, methoxy, cyano or nitro.
14. A compound according to claim 3 wherein Y is O or S.
15. A compound according to claim 1 wherein X¹ is selected from C₁₋₄alkyl, C₂₋₄alkoxyalkyl, C₃₋₄alkenyl, C₃₋₄alkynyl, C₁₋₄haloalkyl, C₃₋₄haloalkenyl, C₃₋₄haloalkynyl or cyanomethyl.
16. A compound according to claim 1 wherein X² is selected from H, methyl or a bivalent radical of formula (CH₂)₂ or (CH₂)₃ which forms a 5- or 6-membered ring with the Ar group.
17. A compound of formula II:

- 74 -



wherein:

- R¹ is hydrogen, C₁₋₄ alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or
 5 di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy,
 aryloxy, C₁₋₄alkylthio, or aryl;

Z is CH or N;

- 10 Alk is C₁₋₆alkylene;


R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

- X¹ is C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl
 15 optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio;
 and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂-
 forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

20

18. A compound of formula III:



wherein:

R¹ is hydrogen, C₁₋₄ alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy, aryloxy, C₁₋₄alkylthio, or aryl;

A is a bond or CH₂O;


Alk is C₁₋₇alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

19. A compound of formula IV



wherein:

- 76 -

R¹ is hydrogen, C₁₋₄ alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, aryloxy, C₁₋₄alkylthio, or aryl;

5 Z is CH or N;

Alk is C₁₋₆alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;


10

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂-

15 forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

20. A compound of formula V



V

20 wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxaliny, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

25 Z is CH or N;


Alk is C₁₋₆alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl
 5 optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio;
 and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂-
 10 forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

21. A compound of formula VI



wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or
 15 quinoxalinyl, each of which may be optionally substituted with 1 to 3 substituents
 selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

A is a direct bond, O, NH or NMe;

20 Alk is C₁₋₆ alkylene;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;


X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl
 25 optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio;
 and

- 78 -

X^2 is hydrogen, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.


22. A compound of formula I as described in any one of Tables 1 to 8.

23. A compound of formula VII:



10 where A, Alk, W, Ar and X^2 are as defined in claim 1, and X^3 is X^1 or an oxime protecting group.

24. A compound of formula X




where Het, A, Alk, W, Ar and X^2 are as defined in claim 1.

25. A composition comprising a compound of formula I according to claim 1 together
20 with a pharmaceutically acceptable carrier.

26. A composition according to claim 25 which is a pharmaceutical composition.

27. A pharmaceutical composition comprising a compound of formula I





a salt thereof or a pharmaceutically acceptable derivative thereof where



- 79 -

Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical;

5 A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



10



- 80 -

where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C₂₋₄alkylene radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

5

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

10

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen or C₁₋₆alkyl; and

15

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

Alk is C₁₋₇alkylene or a direct bond;

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

20

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;

25

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or C₁₋₄alkylthio; and

30

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;

- 81 -

a pharmaceutically acceptable carrier and further including a known anti-viral or anti-retroviral agent or other pharmaceutical used in the treatment of viral infections.




28. A method for the treatment or prophylaxis of a picornavirus infection in a mammal including the step of administering an effective amount of a compound of formula I




a salt thereof or a pharmaceutically acceptable derivative thereof where

10 Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical;

A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



- 82 -



5 where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C₂₋₄alkylene radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

10 Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

15 R⁴ is hydrogen or C₁₋₆alkyl; and

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

Alk is C₁₋₇alkylene or a direct bond;

20

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;

25

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or

- 83 -


C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar.

5

29. A method of claim 27 wherein the picornaviral infection is caused by one or more serotypes of rhinovirus.


30. Use of a compound of formula I




a salt thereof or a pharmaceutically acceptable derivative thereof where

Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an
15 optionally substituted 9- or 10-membered bicyclic heterocyclic radical;



A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



20



- 84 -



5 where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C₂₋₄alkylene radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

10

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

15

R⁴ is hydrogen or C₁₋₆alkyl; and

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

20 Alk is C₁₋₇alkylene or a direct bond;

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl
5 substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or
C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar in the manufacture of a medicament for the treatment or prophylaxis of picornavirus infection in mammals.

31. Use according to claim 30 wherein the picornavirus infection is one caused by one or more of the serotypes of rhinovirus.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78746 A1

(51) International Patent Classification⁷: C07D 401/04,
403/04, 261/08, 237/10, 417/04, A61K 31/501, 31/42,
31/50, 31/4453, A61P 31/12

Waverley, VIC 3149 (AU). KRIPPNER, Guy [AU/AU];
58 Cypress Avenue, Glen Waverley, VIC 3150 (AU).

(21) International Application Number: PCT/AU00/00680

(74) Agents: CAINE, Michael, James et al.; Davies Collison
Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(22) International Filing Date: 16 June 2000 (16.06.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PQ 1054 18 June 1999 (18.06.1999) AU

(71) Applicant (for all designated States except US): BIOTA
SCIENTIFIC MANAGEMENT PTY LTD [AU/AU];
616 St Kilda Road, Melbourne, VIC 3004 (AU).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WU, Wen-Yang
[AU/AU]; 34 Munro Avenue, Mount Waverley, VIC 3149
(AU). WATSON, Keith [AU/AU]; 23 Erasmus Street,
Surrey Hills, VIC 3127 (AU). MCCONNELL, Darryl
[AU/AU]; 18 Outlook Drive, Mount Waverley, VIC 3149
(AU). JIN, Betty [AU/AU]; 34 Munro Avenue, Mount

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIVIRAL AGENTS

(57) Abstract: This invention relates to compounds of formula (I): Het-A-Alk-W-Ar-C(X²)=NO-X¹, their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel intermediates useful in the preparation of the compounds of formula (I).

WO 00/78746 A1

EXPRESS MAIL NO. EV06483993/US

FTO/SB/01 (10-01) (modified)

Please type a plus sign (+) inside this box



DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket No.	150070.401USPC	
	First Named Inventor	Wen-Yang Wu	
	COMPLETE IF KNOWN		
	Application Number	10/018,963	
	Filing Date	December 18, 2001	
	Group Art Unit	Not yet known	
<input type="checkbox"/> Declaration Submitted with Initial Filing <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing		Examiner's Name	Not yet known

As the below named inventor(s), I/we hereby declare that:
My residence, post office address, and citizenship are as stated below next to my name.
I/we believe that I/we are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANTIVIRAL AGENTS
(Title of Invention)

the specification of which was filed on (MM/DD/YYYY) June 16, 2000 the specification of which is attached hereto ☐

as United States Application Number or PCT International Application Number PCT/AU00/00680 Express Mail No. ☐

and was amended on (MM/DD/YYYY) (if applicable) ☐

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

In addition, I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable.

I/we hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Claimed	Certified Copy Attached?	
				YES	NO
PQ 1054	AU	June 18, 1999	Y		X
PCT/AU00/00680	WO	June 16, 2000	Y		X

Additional foreign application numbers are not listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I/we hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application No.	Filing Date (MM/DD/YYYY)	Application No.	Filing Date (MM/DD/YYYY)
Additional provisional application numbers are not listed on a supplemental priority data sheet PTO/SB/02B attached hereto.			

Direct all communications to Customer Number 00500--

Name	Karl R. Hermanns			of SEED INTELLECTUAL PROPERTY LAW GROUP PLLC		
Address	701 Fifth Avenue, Suite 6300					
City	Seattle	State	WA	Zip	98104-7092	
Country	U.S.A.	Telephone	(206) 622-4900	Fax	(206) 682-6031	

Please type a plus sign (+) inside this box → +

EXPRESS MAIL NO. EV064839937US

PTO/SB/61 (10-00)

Approved for use through 10/31/2002 OMB 0651-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ELECTION AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT	Application Number	10/018,963
	Filing Date	December 18, 2001
	First Named Inventor	Wen-Yang Wu
	Group Art Unit	Not yet known
	Examiner Name	Not yet known
	Attorney Docket Number	150070.401USPC

I hereby appoint:

☒ Practitioners at Seed IP Law Group PLLC

OR

☐ Practitioner(s) named below



00500

PATENT TRADEMARK OFFICE

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith

Please change the correspondence address for the above-identified application to.

☐ The above-mentioned Customer Number

OR

☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the.

☐ Applicant/Inventor

☒ Assignee of record of the entire interest See 37 CFR 3.71

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ As assignee of record of the entire interest hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventor

SIGNATURE of Applicant or Assignee of Record

Name ☒ Richard A. Wadley

Signature ☒ [Signature]

Date 27 February 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*

☒ *Total of 4 forms are submitted.

Burden Hour Statement. This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

D:\NP\PortB\NManage\KRISTINA\246678_1.DOC [01-14-01]

I/we hereby declare that all statements made herein of my/our own knowledge are true and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

100

Sole or First Inventor:		Wen-Yang Wu					
Given Name (first and middle (if any))				Family Name or Surname			
Wen-Yang				Wu			
Inventor's Signature	x	<i>[Signature]</i>			Date	x 30 January 2002	
Residence: City	Mount Waverley	State	Victoria	Country	AU	Citizenship	AU
Post Office Address	34 Munro Avenue						
City	Mount Waverley	State	Victoria 3149	Country	AU		

300

Additional Inventor:		Keith Watson					
Given Name (first and middle (if any))				Family Name or Surname			
Keith				Watson			
Inventor's Signature	x	<i>[Signature]</i>			Date	x 25 January 2002	
Residence: City	Surrey Hills	State	Victoria	Country	AU	Citizenship	AU
Post Office Address	23 Erasmus Street						
City	Surrey Hills	State	Victoria 3127	Country	AU		

300

Additional Inventor:		Darryl McConnell					
Given Name (first and middle (if any))				Family Name or Surname			
Darryl				McConnell			
Inventor's Signature	x	<i>[Signature]</i>			Date	x 13 February 2002	
Residence: City	Mount Waverley	State	Victoria	Country	AU	Citizenship	AU
Post Office Address	18 Outlook Drive						
City	Mount Waverley	State	Victoria 3149	Country	AU		

400

Additional Inventor:		Betty Jin					
Given Name (first and middle (if any))				Family Name or Surname			
Betty				Jin			
Inventor's Signature	x	<i>[Signature]</i>			Date	x 30 January 2002	
Residence: City	Mount Waverley	State	Victoria	Country	AU	Citizenship	AU
Post Office Address	34 Munro Avenue						
City	Mount Waverley	State	Victoria 3149	Country	AU		

500

Additional Inventor		Guy Krippner	
Given Name (first and middle (if any))		Family Name or Surname	
Guy		Krippner	
Inventor's Signature	x <i>Guy Krippner</i>		Date
Residence: City	Glen Waverley	State	Victoria
		Country	AU
Post Office Address	58 Cypress Avenue		
City	Glen Waverley	State	Victoria 3150
		Country	AU
No additional inventors are being named on supplemental Additional Inventor(s) sheets PTO/SB02A attached hereto.			